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CHAPTER 1 – THE MARINE POTENTIAL 
1.1. Chemistry in the oceans 
More than 60% of the earth’s biosphere is made up by oceans, which represent an 
endless source of compounds with interesting pharmacological activity.1 The remarkable 
biodiversity within the marine environment is guaranteed by the coexistence of an 
enormous number of species, which interact with each other and with the environment in 
different ways. In this process, chemistry plays an essential role: all the marine organisms 
synthesize or obtain from symbiotic microorganisms “secondary metabolites”, molecules 
with even very complex structures, which are characteristic of specific species or specific 
taxa. Many secondary metabolites are involved in the interactions within or between 
species. Considering the number of different species and their immeasurable possible 
interactions, it’s not a surprise that a wide variety of secondary metabolites are produced 
to preserve and improve the life of the producing organisms.   
It’s very well known that plants are particularly rich in secondary metabolites, and their 
properties have been long exploited for the treatment of diseases. In the last decades, the 
progress in some technologies and the wider availability of diving equipment made it 
possible to extend this research to marine organisms.  
A larger number of organisms and less genetic homogeneity between separate 
populations of the same species exist in the marine compared to the terrestrial 
environment. This results in a higher structural diversity at the molecular level. Among 
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marine organisms, the chance of finding bioactive compounds is remarkably higher in 
some invertebrates, like corals, tunicates, and sponges. Many of these compounds are  
involved in the chemical defence of these organisms, essential for their survival since they 
are sessile organisms often lacking any physical defence from the predators.  
Even when showing interesting and specific pharmacological activities, natural 
compounds isolated from marine organisms rarely raise the interest of pharmaceuticals 
companies, because they are difficult to obtain in sufficient amounts for clinical use. Total 
synthesis is a possible way to overcome this problem, but this option is usually prevented 
by the complex structure of many natural products, often including many chiral centers, 
which make the chemical synthesis particularly challenging and this option economically 
unfeasible. 
In this case, tapping the natural source is the best option. The problem is to conciliate 
development dynamics necessary for man and protection of the marine environment and 
biodiversity. Oceans are showing increasing signs of overexploitation and degradation, 
resulting in loss of both productivity and biodiversity. In this context, a massive collection 
of marine organisms producing compounds of industrial interest appears unrealistic. 
Alternative approaches have therefore been proposed, such as the cultivation of the 
organism of interest under controlled conditions (aquaculture), and the laboratory 
production of metabolites in bioreactors from cell cultures. A more recent approach, 
which, in the light of the explosive development of molecular biotechnologies is rapidly 
gaining a prominent position worldwide, is the study of the metabolic processes leading 
to the synthesis of secondary metabolites. The understanding of these processes at the 
genetic level is paving the way to the possibility to control them, and eventually to 
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produce the desired metabolites in large scale using a "green technology" such as gene 
cloning.  
The research work described in this PhD Thesis was performed at the Dipartimento di 
Chimica delle Sostanze Naturali of Università di Napoli "Federico II", and was addressed to 
different aspects of the research on marine natural products. On one hand, part of the 
research was directed to the "core activity" of natural product chemistry, i.e. isolation and 
structure elucidation of new compounds from marine organisms (produced by their 
symbiotic microorganisms?). In this respect, particular attention was paid to metabolites 
isolated from the marine sponges Plakortis simplex,1,2 Plakortis sp. and Theonella 
swinhoei.3 
On the other hand, a new research project was started up and focused on the synthesis of 
endoperoxide derivatives based on the plakortin scaffold. Plakortin is an endoperoxide 
polyketide  with interesting antimalarial properties which was isolated from the marine 
sponge Plakortis simplex and is probably produced by an uncultivable symbiotic 
microorganism of the sponge.  
 
1.2. Porifera 
Marine sponges (Porifera) have been the only object of the chemical investigation carried 
out during my Ph.D., and described in this thesis. 
Porifera constitute the simplest and most ancient phylum among metazoans. They are 
ubiquitous animals and live permanently attached to a location in the water. There are 
from 5,000 to 10,000 known species of sponges. Most sponges live in salt water; only 
about 150 species live in fresh water. Their body consists of specialized tube-like cells 
called porocytes which control channels leading to the interior of mesohyl (ostia). 
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Mesohyl is the gelatinous matrix within the sponge made of collagen and covered by 
choanocytes, cylindrical flagellated cells. The outer layer is formed by pinacocytes, plate-
like cells which digest food particles too large to enter the ostia. 
 
 
Figure 1.1. A sponge body structure  
 
The body is reinforced by the skeleton, collagen fibers and spicules: Calcareous sponges 
produce spicules made of silica calcium carbonate while the larger class (90%) of 
Demonspongiae produce a special form of collagen called spongin besides silica spicules; 
glass sponges, common in polar water and in the depths of temperate and tropical seas 
contain synctia in their structure which enable them to extract food from these resource-
poor waters with the minimum of effort. Sponges are filters feeders; they obtain 
nourishment, tiny and floating organic particles, plankton and oxygen from flowing water 
that they filter through their body. Water flows into a sponge through porocytes and 
flows out of it through large opening called oscula. The flowing water also carries out 
waste products. 
The simplest body structure in sponges is a tube or vase shape known as asconoid; in 
siconoids the body wall is pleated and the pumping capacity is increased; leuconoids 
mesohyl 
osculum 
pinacocytes 
choanocytes 
ostia 
skeleton 
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contain a network of chambers lined with choanocytes and connected to each other and 
to the water intakes and outlet by tubes.  
                         
Figure 1.2: Sponge classification: a. asconoid; b. siconoids; c. leuconoids 
 
Most sponges are hermaphrodites (each adult can act as either the female or the male in 
reproduction). Fertilization is internal in most species; some released sperm randomly 
float to another sponge with the water current. If a sperm is caught by another sponge's 
collar cells (choanocytes), fertilization of an egg by the travelling sperm takes place inside 
the sponge. The resulting tiny larva is released and is free-swimming; it uses tiny cilia 
(hairs) to propel itself through the water. The larva eventually settles on the sea floor, 
becomes sessile and grows into an adult.  
Some sponges also reproduce asexually; fragments of their body (buds) are broken off by 
water currents and carried to another location, where the sponge will grow into a clone 
of the parent sponge (its DNA is identical to the parent's DNA).  
 
 
 
 
     
  
b. c. a. 
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 (a) (b) 
 
Figure 1.3: Two sponges analyzed in my PhD: (a) Plakortis simplex (b) Theonella swinhoei 
 
The research work carried out during my Ph.D. followed three different projects:   
1. Study of mechanism and antimalarial activity  of plakortin  
2. Isolation and structure elucidation of secondary metabolites from the marine 
sponges Plakortis sp., Plakortis simplex  and Theonella swinhoei 
3. Synthesis of simplified endoperoxide derivates based on the plakortin scaffold  
 
The obtained results have been reported in three papers (cited in the reference chapter) 
already published or sent for publication, while two additional papers are in preparation.  
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CHAPTER 2 - STEREOSTRUCTURAL  
ELUCIDATION METHODS 
Until some decades ago, structural determination of new organic compounds was only 
pursued through the use of chemical techniques (degradation and interconversion of 
functional groups). The development of spectroscopic techniques dramatically changed 
this approach. Today, it is possible to determine complex organic structures, including 
stereochemical details, completely and in a non-destructive way, with submilligram 
samples. Structural determination described in this thesis is largely based on spectroscopic 
techniques, mostly mass spectrometry (MS) and nuclear magnetic resonance (NMR), even 
if in some cases some chemical interconversions were necessary.  
 
2.1 Mass Spectrometry 
The first step in the study of a new bioactive compound is the determination of the 
molecular formula through the high resolution mass spectrometry. Mass spectrometry is 
an analytical technique used to determine the molecular mass of a compound on the basis 
of the mass-to-charge ratio (m/z ratio) of ions produced from the molecules. A very 
accurate measurement of the molecular mass (high resolution mass spectrometry) can 
upgrade the knowledge of the molecule  under investigation providing its molecular 
formula. The source is the component of the mass spectrometer which produces ions from 
the molecule, while the analyzer measures the mass-to-charge ratio of the ions. There are 
many different types of sources, as well as of analyzers. During or after ionization, the 
molecule may fragment, and the mass of the fragments can provide additional 
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information about the structure of the molecule. If the ions do not fragment by 
themselves, they may be induced to fragment by letting them to collide with gas 
molecules. In this case, a second analyzer is used to measure the mass of the fragments. 
This is known as tandem mass spectrometry or MS/MS. 
Most of compounds described in the following sections were analyzed by ESI mass 
spectrometry. The ESI source is technique developed for polar and/or charged 
macromolecules but now it is widely used for a number of molecules, also with not 
marked polarity. The sample is dissolved in a volatile solvent like H2O, MeOH, and CH3CN; 
volatile acids, bases or buffers are often added to the solution. This solution is pumped 
through a charged metal capillary and, in coming out of the capillary, forms a spray. 
Because of the electric potential of the capillary, each droplet of the spray carries an 
excess positive or negative charge, and this causes extensive protonation or 
deprotonation of the molecules of the sample, which become ions. An uncharged carrier 
gas such as nitrogen is used to help the liquid to nebulize and the neutral solvent in the 
droplets to evaporate.  
 
Figure 2.1. A schematic view of electrospray ionization 
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As the solvent evaporates, the ionized analyte molecules become closer and closer, until 
they can escape from the droplet by electrostatic repulsion. For molecules with a high 
molecular weight, the ions may take more than one proton (up to some tens), and 
therefore may have multiple charge. Formation of multiply charged ions allows the 
analysis of high molecular weight molecules such as proteins, because it reduces the m/z 
ratio of the ions, which is therefore easier to measure. 
 
2.2 Nuclear Magnetic Resonance 
The most important spectroscopic technique used for structure elucidation of the isolated 
secondary metabolites has been nuclear magnetic resonance (NMR). In addition to 
standard  1H- and 13C-NMR spectra, a large use of 2D NMR experiments was necessary. 
They provide an important tool for the interpretation of their 1D NMR counterparts and 
are characterized by reasonably long acquisition times (often shorter than the time 
needed to acquire a 13C NMR spectrum), and for the easy assignment of nuclei resonating 
in crowded regions of the spectra (signal overlapping is much less likely in two dimensions 
than in one). 
 
Figure 2.2. A typical COSY spectrum 
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The COSY (Correlation SpectroscopY) experiment is one of the simplest and yet most 
useful 2D NMR experiment. It allows determination of the connectivity of a molecule by 
identifying which protons show scalar couplings. In spite of the many modifications which 
have been proposed along the years, the very basic sequence composed of two π/2 pulses 
separated by the evolution period t1 is still the best choice if one is simply dealing with the 
presence or the absence of a given coupling, but not with the value of the relevant 
coupling constant. 
 
Figure 2.3. The TOCSY spectrum of sucrose 
The TOCSY (Total Correlation SpectroscopY) experiment is a 2D NMR experiment very 
useful in the analysis of molecules composed of many separate spin systems, such as 
oligosaccharides (the TOCSY spectrum of sucrose is shown in Fig. 2.3) or peptides. The 
TOCSY spectrum shows correlation peaks between nuclei that may be not directly 
coupled, but are still within the same spin system. The appearance of a TOCSY spectrum 
resembles in all aspects a COSY; the difference is that the cross peaks in a COSY result 
from coupled spins, whereas in the TOCSY spectra they arise from coherence transfer 
through a chain of spin-spin couplings, and therefore any pair of protons within a spin 
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system may give rise to a peak. The range of the coherence transfer (i.e. through how 
many couplings the coherence may be transferred) increases with increasing mixing times 
(Δ), but a mixing time too long may reduce sensitivity. 
The HSQC (Heteronuclear Single Quantum Correlation) and HMQC (Heteronuclear 
Multiple Quantum Correlation) experiment are 2D NMR heteronuclear correlation 
experiments, in which only one-bond proton-carbon couplings (1JCH) are observed. In 
principle, the HSQC experiment is superior to HMQC in terms of selectivity and 
additionally allows DEPT-style spectral editing. However, the sequence is longer and 
contains a larger number of π pulses, and is therefore much more sensitive to 
instrumental imperfections than HMQC. 
 
Figure 2.4. The HSQC spectrum of sucrose 
The HMBC (Heteronuclear Multiple Bond Correlation) experiment is a heteronuclear two-
and three-bond 1H-13C correlation experiment; its sequence is less efficient than HSQC 
because the involved 2,3JCH couplings are smaller (3-10Hz). Moreover, while 
1JCH are all 
quite close to each other, 2,3JCH can be very different, making necessary the optimization of 
the experiment for each type of coupling. As a consequence, in many HMBC spectra not all 
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of the correlation peaks which could be expected from the structure of the molecule are 
present. 
The ROESY (Rotating-frame Overhauser SpectroscopY) experiment is a chemical shift 
homonuclear correlation which can detect ROEs (Rotating-frame Overhauser Effect). ROE 
is similar to NOE, being related to dipolar coupling between nuclei, and depending on the 
geometric distance between the nuclei. While NOE is positive for small molecules and 
negative for macromolecules, ROE is always positive. Therefore, the ROESY experiment is 
particularly useful for mid-size molecules, which would show a NOE close to zero. 
 
Figure 2.5. The HMBC spectrum of sucrose 
The ROESY sequence is similar to the TOCSY sequence, and unwanted TOCSY correlation 
peaks may be present in the ROESY spectra. Fortunately, these unwanted peaks can be 
easily recognized, because their phase is opposite compared to ROESY correlation peaks. It 
is important to acquire ROESY spectrum in phase-sensitive mode for a correct 
interpretation of the spectrum. 
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2.3 Stereochemistry determination 
The determination of the relative and absolute configuration of natural products 
represents one the most important goals of the structural characterization. The detailed 
knowledge of the tridimensional arrangement of natural products is essential to 
understand the biological activity, the relationships drug-receptor, and to synthesize the 
natural products or its optimized analogues. 
The structure of many natural compounds includes a number of different stereogenic 
centers. Usually, in a step-by-step structural elucidation, the first goal is the identification 
of relative stereochemistry of chiral centers. Then, after the elucidation of absolute 
stereochemistry even at a single stereogenic carbon, it will be possible to deduce the 
absolute configuration of the total structure. Unluckily, when the relative stereochemistry 
of different chiral centers cannot be correlated, the absolute configuration must be 
assigned independently.  
2.3.1 Scalar and spatial NMR couplings 
Through the use of NMR spectroscopy it is possible to obtain information about the 
tridimensional structure of molecules. Evaluation of coupling constants (J) and NOE effects 
are of key importance to this aim.  
The  Karplus’s law4 describes the influence of relative arrangements of protons in a 
molecules on the values of coupling constants (JH-H). 
                                                  3J= Acosθ2 + Bcosθ + C   
This equation evidences that the values of homonuclear (3JH-H) and heteronuclear (
3JC-H) 
coupling constants are related to the value of the dihedral angle θ between atoms. 
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Figure 2.6. The Karplus rule 
Usually the 3JH-H  values are about  0-1,5 Hz, when  θ is 90°, while the greatest are 
observed when  θ is about   0° or 180°, generally  J180° is  hioghest than J0°. Thus, for 
example, it is very easy to discriminate between an axial-axial correlation within a six-
membered ring (3Ja-a~7-9 Hz), and an axial-equatorial or equatorial-equatorial correlations 
(3Ja-e~
3Je-e~2,5 Hz). Furthermore, it is  very easy to discriminate between a cis or a trans 
relationship of two double bond protons, 3Jcis~6-12 Hz, 
3Jtrans ~14-20 Hz. 
Additional information about relative configuration of stereogenic centers can be obtained 
from the so-called NOE effect (N.O.E.: "Nuclear Overhauser Enhancement"). This effect 
can be observed upon irradiation, during the acquisition of the spectra, on a specific 
signal. In this way, the  relaxation times of all the protons surrounding the irradiated 
proton (distance < 2.5 A°), even though not belonging to the same spin system, are 
influenced and thus, their height changes. The NOE effect establishes a spatial relationship 
between substituents of fixed molecules, but this effect is dependent from the dimensions 
of the molecule. Indeed, NOE effects cannot be evidenced for large molecules. To 
overcome this limitation, a two-dimensional omonuclear experiment, the ROESY 
experiment (Rotating-frame Overhauser Effect SpettroscopY), can be used (see above).  
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2.3.2 Murata’s method 
Generally, the use of coupling constants 3JH-H and ROESY correlations is limited to rigid o 
cyclic systems, where the large number of weak interactions limits the possibility of 
conformational motions, and consequently the dihedral angles and interatomic distances 
between the protons are rigidly fixed. However, many biologically active natural products, 
often have linear or flexible macrocyclic structures. Recently, Murata et al. proposed a 
simple method7 based on the evaluation of homo- and heteronuclear coupling constants, 
which may be used to determine the relative stereochemistry of flexible systems, 
especially in those cases where the chiral centers are composed of oxygen-linking 
methines.  
This method is based on the assumption that the conformation of the adjacent 
asymmetric centers, in acyclic systems, is mainly represented by staggered rotamers, and 
their relative stereochemistry can be determined using proton-carbon coupling constants, 
2,3JH-C, and vicinal proton coupling constants, 
3JH-H. The combined use of the values of these 
constants makes possible the identification of the predominant rotamer. An accurate 
measurement of heteronuclear coupling constants can be realized with two-dimensional 
NMR experiments. In many cases it is sufficient a qualitative assessment of the constants, 
achieved through phase-sensitive HMBC experiments, which allow to discriminate 
between large constants (large), and small constants (small).  
2.3.3 Circular Dichroism 
Circular dichroism (CD) spectroscopy of optically active compounds is a powerful method 
for studying the three-dimensional structure o molecules, and can provide information on 
absolute configurations, conformations, etc.  
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The CD spectroscopy takes advantage of the different absorption shown by chiral 
compounds of left and right circularly polarized UV/Vis light. In circularly polarized light, 
the electric field vector rotates about its propagation direction forming a helix in the space 
while propagating. This helix can be left-handed or right-handed, hence the names left and 
right circularly polarized light. 
At a given wavelength, circular dichroism of a substance is the difference between 
absorbance of left circularly polarized and right circularly polarized light:  
ΔA = AL - AR 
Since circular dichroism uses asymmetric electromagnetic radiations, it can distinguish 
between enantiomers. Two enantiomers have the same CD spectra, but with reversed 
sign. 
Of course, in order to show a differential absorbance, the molecules needs to absorb the 
UV/Vis light, and therefore must possess at least one chromophore. If the molecule does 
not have a chromophore, this can be introduced using a derivatization reaction. This is 
why methyl glycosides are benzoylated to determine their absolute configuration. 
One of the most important methods to establish the absolute configuration of a molecule 
is the exciton chirality method. This method is based on the interaction between two 
chromophores. When two or more strongly absorbing chromophores are located around a 
chiral system, their electric transition moments interact spatially (exciton coupling) and 
generate a circular dichroism. Because the theoretical basis of exciton coupling are well 
understood, it is possible to correlate the CD spectrum of an exciton-coupled 
chromophore system with the spatial orientation of the chromophores, which in turn can 
be related to the absolute configuration of the molecule. It is important to point out that, 
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unlike for example optical rotation, the exciton chirality method does not require any 
reference nearby in space and constitute of organic compound to provide the absolute 
configuration of the molecule under study (if its conformation is known). 
2.3.4 Mosher’s method 
Several methods are available for the determination of absolute stereochemistry of 
compounds, however, the most extensively used is undoubtedly the Mosher’s method. 
This method utilizes the preparation of diastereomeric acyl derivatives with the two 
enantiomers of 2-methoxy-2-(trifluoromethyl) phenylacetic acid (MTPA) and evaluation of 
the 1H NMR resonances of the protons surrounding the stereogenic center. In particular, 
the chemical shift differences ∆δS-R must be calculated, after a detailed assignment of 
proton resonances for the two diastereomers obtained. This method has been proposed 
for determination of the absolute configuration of secondary alcohols. The application of 
the Mosher model is based on the existence, in the reaction solution,  of a preferential 
conformation, in which the proton at the stereogenic center, the carbonyl of the ester 
group and the trifluoromethylic group  reside on the same plane.5 This preferential 
conformation is shown in Fig. 2.8. 
 
Figure. 2.7 A schematic view of the Mosher’s method 
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Figure 2.8.  (a) Preferential conformation of Mosher’s model. (b) Mosher’s empiric rule for 
the absolute configuration of secondary alcohols. The groups on the right are 
characterized by Δδ>0 while the groups on the left by Δδ<0 
 
Kakisawa and Kashman proposed some changes to the Mosher’s method including the 
evaluation of ∆δS-R values not only of proton chemical shifts for carbons directly linked to 
the stereogenic center, but also for other protons on the two sides. 
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CHAPTER 3 – ANTIMALARIAL ENDOPEROXIDES. 
ISOLATION AND SYNTHESIS OF NEW COMPOUNDS 
 
3.1. The malaria threat 
Malaria is an infectious disease caused by several protozoans belonging to the genus 
Plasmodium (P. falciparum, P. ovale, P. vivax, P. malariae) but P. falciparum is the parasite 
that causes most severe diseases and most fatal cases. The protozoan comes in contact 
with humans through the vector contribution of female mosquitoes of the genus 
Anopheles. The bite of infected mosquitoes injects protozoans in the sporozoite form, that 
invade selectively the parenchymal cells of the human liver. In this stage, the patient 
remains asymptomatic and, after an average incubation period of 5-7 days (in the case of 
P. falciparum), protozoa reach the merozoite stage and are released from the liver. The 
merozoites invade the erythrocytes and start feeding on the haemoglobin. After 
proliferation, the rupture of the erythrocyte membrane and the consequent liberation of 
other merozoites, that invade other erythrocytes, cause the massive infection and the 
symptoms. A small portion of merozoites develops into the sexual stage of gametocytes, a 
form that is able to re-start the life cycle of the malaria parasite when a mosquito takes a 
blood meal from an infected person.8 
The clinical symptoms of malaria infections are exclusively attributable to parasites in the 
erythrocytic stage. The rupture of infected erythrocytes is associated with the release into 
the blood stream of cell debris responsible for the characteristic fever spike patterns. In 
the lethal cases, a specific protein produced by the protozoan is embedded into the cell 
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membrane of the infected erythrocyte and, as a consequence of this modification, the 
erythrocyte sticks to the walls of capillaries causing obstruction of vessels. When this 
mechanism operates at the level of brain vessels, the loss of consciousness is the first 
symptom, but, if this form of cerebral malaria is not treated immediately, it is soon 
followed by death. 
 
Figure 3.1 The malaria cell cycle 
 
The treatment of malaria infections holds a venerable place in the history of medicinal 
chemistry and of natural product chemistry. As commonly well-known, the first specific 
treatment for malaria dates back to the 17th century when the bark of Cinchona trees was 
used as the best tool to face infections of malaria, that was endemic in Africa, Asia but also 
in several parts of Europe and North America. Later, malaria was the first disease to be 
treated with an active principle isolated from a natural source, quinine  isolated from the 
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Cinchona bark in 1820, and, later again, the first human disease to be treated with a 
synthetic drug (methylene blue in 1891). 
In the course of 20th century, especially during World War II, a series of effective synthetic 
antimalarial drugs have been developed. Among them, chloroquine (2), mefloquine (3), 
and pyrimethamine (4) (Fig. 3.2), became the drugs of choice in several programs and 
contributed to the almost complete eradication of malaria from Europe and North 
America. 
 
Figure 3.2. First-line antimalarial drugs: quinine (1), choloquine (2), mefloquine (3), 
pyrimetamine (4) 
 
Unfortunately, in our days malaria still continues to be an extremely important threat to 
the health and economic prosperity of the human race, constituting a major cause of 
morbidity and mortality in tropical countries of Asia, Africa and South America. The reality 
is probably worse than that commonly conceived: a recent analysis estimates, at a 
minimum, between 700,000 and 2.7 million deaths each year from malaria (over 75% of 
them are African children) and between 400 and 900 million acute febrile episodes per 
year in African children under the age of 5 living in malaria-endemic regions . Part of the 
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reason for the failure to control malaria in these areas is the emergence and spread of 
resistance to first-line antimalarial drugs, cross-resistance between the members of the 
limited number of drug families available, and in some areas, multi-drug resistance. In 
addition, the prevalent spreading of the disease to poor countries has suggested to many 
pharmaceutical companies to categorize malaria as a low priority. In this context, funds 
provided by public agencies, as European Community, are the good news of recent years. 
Their specific aim is to encourage the antimalarial research in spite of the poor economic 
interest. 
Two major breakthroughs of the past few decades have renewed the assault of scientists 
to this infective disease. The first is the complete sequencing of the genome of 
Plasmodium falciparum  that is expected to provide useful information for the 
identification of new drug targets. The second is the discovery by Chinese researchers of 
artemisinin (qinghaosu), an endoperoxide sesquiterpene lactone, as the active principle of 
the sweet wormwood, Artemisia annua, an herbal remedy used in folk Chinese medicine 
for 2000 years. This molecule and its oil soluble (e.g. artemether and arteether) and water 
soluble (e.g. artesunate and artelinate) semi-synthetic derivatives have shown excellent 
efficacy against chloroquine-resistant Plasmodium strains and are becoming increasingly 
used, especially in combination with traditional antimalarials (e.g. mefloquine).  
However, these important discoveries should be considered only as stimulating starting 
points in the continuing fight against malaria. As commonly believed, in spite of several 
efforts, an effective vaccine against all the forms malaria probably will never be 
introduced, and the complete removal of the vector of the transmission is practically 
impossible. Therefore, the need for rapid development and introduction of safe and 
affordable drugs against malaria continues to be urgent.  
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3.2. The efficacy of endoperoxide derivatives 
The sweet wormwood Artemisia annua (Compositae), also named qinghao, has been used 
in Chinese folk medicine for 2000 years, originally as a treatment for haemorrhoids, but 
starting from the III century also to treat fevers. In 1972, after activity-guided 
fractionation, the sesquiterpene derivative artemisinin (in China named qinghaosu: “the 
active principle of qinghao”) was isolated; later its structure was elucidated and it was 
shown to possess a potent antimalarial activity. This molecule soon appeared to constitute 
a major breakthrough in the antimalarial therapy because of: 1) its nanomolar activity on 
chloroquine-resistant P. falciparum strains (higher than the activity on chloroquine-
sensitive ones) even on cerebral malaria; 2) its fast action; 3) the absence of detectable 
toxicity at therapeutic doses. 
 
 
Figure 3.3. Chemical structures of artemisinin (5) and of its semisynthetic derivatives   
artemether (6) and artesunate (7) 
 
Artemisinin (5) is a structurally complex cadinane sesquiterpene lactone bearing an 
endoperoxide group embedded in a 1,2,4-trioxane ring. With its unique juxtaposition of 
peracetal, acetal and lactone functionalities, it has very much to interest organic chemists.  
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Since the relatively efficient totally synthetic routes developed9 will very unlikely supplant 
the natural source, an intense scientific activity has been carried out entailed to the 
chemical derivatization of artemisinin. The aim was to obtain compounds with better 
solubility, higher stability, and thus with increased formulation characteristics, and, 
possibly devoid of the neurotoxic side effects detected for the natural molecule. 
These efforts soon resulted in the recognition that the endoperoxide linkage is an 
essential feature for antimalarial activity, given that the acyclic diol and the ether (1,3-
dioxolane) analogues of artemisinin were completely devoid of activity. Consequently, the 
lactone group became the main site for chemical variations that bore the preparation of 
the oil-soluble artemether (6) (Fig. 3.3), and the water-soluble artesunate (7). Although 
these molecules are now used for treatment of severe malaria with the support of the 
World Health Organization, unfortunately, they still possess neurotoxic activity. As a result 
of the continuing synthetic studies, several artemisinin derivatives, some of which surpass 
the parent compound in antimalarial potency, have been prepared but many of them 
show toxicity or have unfavourable pharmacokinetic features. An essential requirement to 
design optimized artemisinin derivatives would be a perfect knowledge of the mechanism 
of its antimalarial activity. Unfortunately, still today our knowledge appears incomplete. 
While the crucial importance of the endoperoxide pharmacophore is no longer 
questioned, the detailed mechanism of action of this molecule is still not unanimously 
accepted. According to a first hypothesis, artemisinin (or its analogues) would interact, 
within the parasite food vacuole, with the iron center of the heme unit released during the 
digestion of hemoglobin. The interaction of artemisinin with the heme ferrous iron would 
cause the cleavage of the peroxide bridge and the formation of alkoxy radicals that, after 
several rearrangements, would result in the formation of free C-centered radicals (see 
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below, Figure 3.11). These should be toxic to the parasite because they should alkylate not 
better defined “sensitive” macromolecular targets. This hypothesis is based on the 
evidence that, in several experimental models, artemisinin reacts with iron ions and in 
particular it interacts strongly with hemin (ferriprotoporphyrin IX) and its ferrous form 
(ferroprotoporphyrin IX) to give covalent adducts.  
Some researchers have proposed for artemisinin the interaction with a specific target. This 
has been identified as a Ca2+-dependent ATPase specific of P. falciparum (PfATP6), a trans-
membrane protein associated with the parasite endoplasmic reticulum. However, it is still 
not clear whether artemisinin reacts with this target as it is (and, therefore, the peroxide 
bridge exerts its key role concomitantly with the binding), or it needs a foregoing reaction 
with an iron-containing molecule.  
Further experiments would be required to gain more insights into the mechanism of 
action of the endoperoxide-containing antimalarial agents. The isolation of different 
antimalarial endoperoxides from natural sources can evidently help in this task. Indeed, it 
could provide additional information about the structural features required to the carbon 
backbone of a endoperoxide-containing antimalarial agent. With luck, this research could 
afford new natural compounds whose antimalarial activity is higher than that of 
artemisinin. In this context, with the inspiration of artemisinin, several research groups are 
currently engaged in the isolation of endoperoxide-containing compounds from terrestrial 
plants and marine organisms. 
 
3.2.1. Marine Endoperoxides 
A large number of cyclic peroxides have been isolated from marine organisms and some of 
them have been tested for antimalarial activity. Marine sponges belonging to the family 
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Plakinidae contain a series of simple endoperoxide derivatives that have been identified as 
polyketide metabolites possessing six- or five-membered 1,2-dioxygenated rings (1,2-
dioxane or 1,2-dioxolane, respectively). A further variation is represented, in some cases, 
by the presence of a 3-methoxy substitution, building a peroxyketal group.  
The parent compound of this group of secondary metabolites is plakortin (8) (Fig. 3.4), 
that was isolated more than 25 years ago from Plakortis halichondroides. This interesting 
secondary metabolite, whose polyketide skeleton suggests the involvement of butyrate 
units in the biogenesis, has been recently re-isolated in remarkable amounts from the 
Caribbean sponge Plakortis simplex.10 In the same study the absolute configuration of the 
four stereogenic carbons of plakortin has been determined by means of chemical 
derivatization and reaction with chiral auxiliaries; in addition, a closely related analogue, 
named dihydroplakortin (9), (Fig. 3.3), has been obtained.10  
 
 
                    Figure 3.4. Chemical structures of plakortin (8) and dihydroplakortin (9)   
 
At the time of its first isolation, plakortin was found to be a weak antibacterial agent, but a 
recent study has finally disclosed the antimalarial potential of this molecule.11 Using the 
pLDH assay, plakortin (8) and dihydroplakortin (9) were assayed against D10, chloroquine-
sensitive strain, and W2, chloroquine-resistant strain of P. falciparum. The two compounds 
showed a good activity, that was more potent on the W2 strain (IC50 = ab. 250 ng/mL on 
D10; ab. 180 ng/mL on W2). In addition, the two compounds proved to be non-cytotoxic in 
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vitro.10 Interestingly, in the same investigation11 the structurally related, even more 
sterically hindered, five-membered endoperoxide plakortide E (10) (Fig. 3.4) was found to 
be inactive 
 
Figure 3.5. Chemical structure of the inactive plakortide E (10) 
The chemical structure of these two antimalarial leads is remarkably simple and thus they 
could constitute a good probe to establish structure-activity relationships, to check the 
currently postulated mechanisms of action for antimalarial peroxides and to prepare semi-
synthetic or totally synthetic derivatives. In this regard, a synthetic study toward this class 
of cyclic peroxides has recently appeared.12 
Some 1,2-dioxane derivatives structurally related to plakortin have been isolated from 
Plakinidae sponges and tested for their antimalarial activity. Plakortide F (11) (Fig. 3.6) has 
been isolated from a Plakortis sp.13 and it has been shown to possess an antimalarial 
activity that is slightly lower (about one half) compared to that of plakortin: IC50 = 480 
ng/mL on D10; ab. 390 ng/mL on W2; however, unless plakortin, this molecule was found 
to be consistently cytotoxic since the IC50 of toxicity against human colon carcinoma and 
mouse lymphoma cells is only about double (IC50 = 1.25 μg/mL) than the concentration of 
the antimalarial activity.  
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                 Figure 3.6. Chemical structures of plakortides F (11), K (12) and L (13)  
 
A very moderate antimalarial activity was also recently reported for plakortide K (12) (Fig. 
3.6), an 1,2-dioxane derivative substituted at position 3 with an unsaturated ketone, 
isolated from a Jamaican sponge Plakortis sp.14. This molecule showed activity against W2 
P. falciparum strain with IC50 = 570 ng/mL and a selectivity index > 8.4. Interestingly, 
plakortide L (13) (Fig. 3.6), a closely related analogue lacking the carbonyl function, was 
completely inactive. Two additional plakortides, named plakortide O (14) (Fig. 3.7) and 
plakortide P (15) (Fig. 3.7), have been isolated from Plakortis halichondrioides and tested 
for antimalarial activity against P. falciparum.15 These compounds showed a very low 
activity with an IC50 = 8 μg/mL for plakortide O and an IC50 > 50 μg/mL for plakortide P. In 
addition, these molecules showed toxicity in vitro toward several cell lines at lower 
concentrations. 
 
 
Figure 3.7. Chemical structures of plakortides O (14), and P (15) 
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It should be noted that all these plakortides have a close structural similarity with 
plakortin and, therefore, their lower level of antimalarial activity can be utilized to gain 
useful information about the structure-activity relationships within this class of simple 
cycloeproxide derivatives. One of the main differences among these compounds are 
ascribable to the stereochemistry. Indeed, while in the structure of plakortin the most 
hindered chains attached to the 1,2-dioxane ring are in cis orientation, in the other 
analogues a trans orientation is present. Most likely, these latter molecules experience a 
more problematic approach of the endoperoxide group to its target. However, the 
chemical structure of the side chains must be also important, as indicated by the marked 
difference of activity between plakortides K (12) and L (13) and between plakortides O (14) 
and P (15).   
 Further information on the structure-activity relationships come from data on synthetic 
and natural 3-alkoxy-1,2-dioxene and 3-alkoxy-1,2-dioxane (both peroxyketals) 
derivatives, which were shown to possess a very good antimalarial activity. In this class of 
molecules, the alkoxy substituent at position 3 could partly mime the non-peroxidic 
oxygen atom of the 1,2,4-trioxane ring of artemisinin. 
 
 
    Figure 3.8. Chemical structures of peroxyplakoric acids A3 (16) and B3 (17) methyl esters  
 
The methyl esters of peroxyplakoric acids A3 (16) and B3 (17) (Fig. 3.8), isolated from 
Plakortis sp., showed a very good antimalarial activity against P. falciparum with IC50 = 50 
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ng/mL and a good selective toxicity index (about 200).16 Through the syntheses of some 
analogues of these active compounds, some conclusions about the structural 
requirements within these classes of antimalarials were drawn. For example, compound 
(18) (Fig. 3.9) proved to be almost completely inactive, whereas compound (19) (Fig. 3.9) 
retained the in vitro activity of peroxyplakoric acid B3 methyl ester, indicating the 
importance of the side chain for the antimalarial activity.17   
 
 
                    Figure 3.9. Two synthetic analogues of peroxyplakoric acids methyl esters 
 
When compound 19 was examined through an in vivo system against P. berghei infection, 
it showed little antimalarial potency because of lability in mouse serum. This undesired 
finding was demonstrated to be due to the hydrolysis of the ester function to the inactive 
carboxylic acid. Indeed, the monoethyl amide analogue of 19, that is stable to hydrolysis in 
the serum, showed a good in vivo activity.18  
Finally, the low antimalarial activity observed for two additional marine endoperoxides 
strictly related to peroxyplakoric acid B3 methyl ester, namely chondrillin, (20) (Fig. 3.10)
19 
and muqubilone,20 (21) (Fig. 3.10)  provides other interesting suggestions. The insertion of 
a double bond within the 1,2-dioxane ring appears to be detrimental for the activity, while 
the presence of the methoxy group at C-3 exerts a pivotal role in the determination of the 
antimalarial activity for this group of molecules. Most likely, simple 1,2-dioxane molecules, 
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that, like plakortin, are consistently active, possess other features that are able to 
compensate the lack of the methoxy group.  
 
                     Figure 3.10. Chemical structures of chondrillin (20) and muqubilone (21) 
  
3.3. Investigation of the plakortin mechanism of action21 
The knowledge of further details on the mechanism of action constituted an issue of key 
importance to continue the investigation on the antimalarial activity of plakortin 
derivatives. Indeed, a more detailed comprehension of the mechanism of action of 
plakortins is essential for the development of totally synthetic simplified derivatives 
containing only the essential pharmacophoric portion of the plakortin scaffold.  
Despite the large use of artemisinin, the exact molecular mechanism underlying its 
biological activity, and that of related antimalarial endoperoxides, is still a matter of 
debate.22 Nevertheless, the ability of these molecules to interact with Fe(II)-heme and to 
produce oxidative stress hallmarks in the plasmodium and in the infected host cells has 
been proved.22,23 
 The reaction of endoperoxides with Fe(II) involves a one electron reduction leading to the 
cleavage of the oxygen-oxygen linkage with the consequent formation of an oxygen anion 
[bound to Fe(III)] and of an oxygen free radical. Two possible evolutions of the generated 
oxygen radical have been postulated for artemisinin (Figure 11). In pathway 1, the oxygen 
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O1 free radical evolves through an intramolecular 1,5-H shift leading to a secondary free 
radical at C4. Alternatively, in pathway 2, the oxygen O2  free radical evolves through a 
homolytic cleavage of the C3-C4 bond resulting in the formation of a primary C4 free 
radical, the driving force being the acquisition of thermodynamic stability by formation of 
the acetate group. 22  
Experimental data24 and theoretical studies25  show controversial results on the more 
relevant pathway for antimalarial activity. Anyway, reported structure-activity relationship 
(SAR) studies on artemisinin26 (Fig. 3.11), as well as on other endoperoxide derivatives,27 
failed to relate in vitro antimalarial activity with a mechanism of action principally based 
on reaction pathway 2. In addition, the lack of antimalarial activity of artemisinin 
analogues with α-oriented substituents at C-4 can be related to their inability to undergo 
the intramolecular 1,5 H-shift (pathway 1)26. 
The crucial role of the endoperoxide function and of 1,2-dioxane ring conformation that 
we have demonstrated for (8), together with the lack of stereoselectivity in its antimalarial 
mechanism of action (3-epiplakortin showed the same activity as (8), strongly indicated 
that plakortin, similarly to artemisinin, should not interact with a specific protein target 
but rather with a Fe(II) ion, most likely the heme iron deriving from hemoglobin 
digestion27. 
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Figure 3.11. Schematic representation of the artemisinin postulated mechanism of action 
 
Our previous conclusion that the antimalarial activity of plakortin and analogues is 
strongly affected by conformational parameters prompted us to speculate on a through-
space reaction pathway for the formation of reactive species responsible for plasmodium 
death. Starting from this assumption, we carried out our investigation on plakortin and 
dihydroplakortin, two related compounds which showed comparable antimalarial activity 
(Table 3.1). The aim was to enlighten, for both these compounds, the steps following the 
reductive activation of the oxygen-oxygen bond by Fe(II) species and yielding to the death 
of the parasite. 
 
Table 3.1. In vitro antimalarial  activity of some Plakortis endoperoxide derivatives   
against D10 (CQ-S) and W2 (CQ-R) strains of Plasmodium falciparum. 
 D10 
IC50 μM 
W2 
IC50 μM 
Plakortin    0.87  0.35 0.39  0.13 
Dihydroplakortin   0.90  0.56 0.43  0.16 
Plakortide K    Not Available > 2 
Artemisinin   0.013  0.004 0.009  0.005 
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 Our approach followed two independent methods based on computational analysis and 
chemical evidences and represents the first investigation on the mechanism of action of 
non-peroxyketal simple dioxane antimalarials. In this thesis, I will report details about the 
experimental studies, while for the computational investigation (carried out in 
collaboration with the group of prof. C. Fattorusso) only significant results will be 
provided. 
 
3.3.1 Computational Studies 
Semi-empirical (PM6) quantum-mechanical (QM) calculations indicated that Chair A is by 
far the most representative 1,2-dioxane ring conformational family for both plakortin and 
dihydroplakortin (Figure 3.12).  
 
Figure 3.12 Family of conformations for plakortin and dihydroplakortin 
 
Subsequent calculations were performed on the basis of the hypothesized reaction 
pathway responsible for antimalarial activity. The first reaction step, activation step, 
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involves a one-electron reduction by heme Fe(II), thus leading to the cleavage of the 
endoperoxide bond, through a dissociative electron transfer (DET) mechanism.28,29 Within 
this step, an oxygen anion [bound to Fe(III)] and an oxygen free radical are produced. 
Since the endoperoxide linkage has two oxygen atoms exposed to heme iron (named O1 
and O2), ab initio calculations were performed in order to investigate the alternative 
formation of O1 and O2 radicals. Results indicated unambiguously a higher stability for O1 
radical. Since the energies of transition states for the two alternative homolytic cleavage 
reactions are likely  in proportion to those of the corresponding products (oxygen 
radicals), we can assume that the formation of the O1 radical is kinetically preferred both 
for 8 and 9 (Fig. 3.6). 
Accordingly, we continued our investigation with the assumption that the radical is 
preferentially formed on O1. An evaluation of the distances between the endoperoxide 
oxygen O1 and the possible partners for an intramolecular radical shift through an analysis 
of conformational search results suggested the double bond of plakortin and the 
methylene hydrogens at C13 of dihydroplakortin as the most likely partners for interaction 
with the O1-oxygen radical. Indeed, our calculations suggested that, as a consequence of 
the conformational rearrangement following the cleavage of the endoperoxide bond, in 
both compounds, the O1-centered radical approached to the “western” alkyl side chain 
[i.e., double bond in 8 and C(13)H in 9, respectively] shrinking from the ester side chain 
[i.e., C(2)H]. This conformational shift is in agreement with the previously explored SARs 
on 1,2-dioxane derivatives that indicated a negligible role for the “eastern” ester side 
chain. On the other hand, the role of the “western” alkyl side chain for the antimalarial 
activity of 1,2-dioxanes is well highlighted by plakortide K (12) (Fig. 3.6). This compound, 
obtained from Plakortis sp.,30  proved to be completely inactive as antimalarial agent 
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(Table 3.1), in spite of its similarity to plakortin, including an identical ester side chain. In 
agreement with our results, the lack of activity should be ascribed to the presence of the 
Δ7,8 trans double bond, whose geometry prevents the location of a reaction partner on the 
western side chain at a distance suitable for the intramolecular shift. 
Taken together, all the computational outcomes indicated the structures reported in 
Figure 3.13 as putative plakortin and dihydroplakortin bioactive conformations, being able 
to undergo: 1) a one electron reduction reaction of the endoperoxide bond by heme Fe(II) 
through a DET mechanism, leading to the formation of an oxygen radical at O1; 2) a 
subsequent through-space one electron reaction between O1 radical and the double bond 
(C9), in the case of plakortin, and between O1 radical and an ethyl chain (C13) hydrogen, 
in the case of dihydroplakortin. The generated carbon radicals could represent, according 
to the hypothesized mechanism of action, toxic intermediates responsible for subsequent 
reactions leading to plasmodium death.  
 
 
 
Figure 3.13. The bioactive conformation for plakortin (green) and dihydroplakortin      
/yellow) 
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3.3.2 Reaction with Fe(II) chloride 
To check experimentally the results of computational calculations, we decided to utilize 
the model Fe(II)-induced reduction of the endoperoxide bond31 and to analyze the 
behavior of both 9 and 8 by detailed characterization of their degradation products. 
Among the possible experimental models, we preferred the use of (inorganic) salts of 
Fe(II) in aqueous solution due to the efficiency and reproducibility of the reaction.32 Data 
available in the literature for artemisinin and other endoperoxide antimalarials are almost 
exclusively based on the use of Fe(II) chloride, sulphate, or gluconate.33 A recently 
appeared investigation has established that Fe(II) chloride is very efficient in triggering 
artemisinin endoperoxide bond cleavage and subsequent intramolecular rearrangement.31   
Thus, dihydroplakortin was allowed to react with FeCl2 in CH3CN/H2O 4:1 at r.t. for 2 
hours. Chromatographic purification of the reaction mixture afforded two major products 
(9a and 9b), whose stereostructure has been identified by detailed spectroscopic 
investigation (Fig. 3.14).  
 
Figure 3.14. Products obtained upon reaction of bot plakortin (8) and dihydroplakortin (9) 
with iron(II)chloride 
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Compound 9a showed ESIMS molecular ions at m/z 373 and 375 [M+Na]+ (relative 
intensity approx. 3:1), an isotopic pattern suggesting the presence of a chlorine atom. This 
was confirmed by HR-EIMS, which indicated the molecular formula C18H35ClO4, with one 
unsaturation degree. Since the methyl ester group is still present in compound 9a (δC 
174.6; δC 51.0, δH 3.72), the molecule must be acyclic. Analysis of the 2D COSY and HSQC 
spectrum of 9a allowed us to disclose two distinct spin systems [highlighted in Fig. 3.15], 
which strictly mirrored the spin systems of dihydroplakortin, with more significant 
differences restricted to the “western” moiety. Within this moiety, the attachment of the 
chlorine atom at C13 (δH 4.53, δC 64.2) resulted from the COSY coupling of H13 with the 
relatively deshielded methyl protons at δH 1.45 (H3-14) and with the methine H8 (δH 1.83), 
this latter proton belonging to a 6-carbon linear chain (from C7 to C12). The HMBC 
spectrum of 9a confirmed this assignment and allowed the complete elucidation of the 
planar structure of compound 9a. Most significant HMBC cross-peaks are reported in (Fig. 
3.15). Elucidation of absolute configuration at the single newly created chiral center C13 
was not trivial. To solve this issue, the J-based configuration analysis proposed by Murata 
for relative configurations in acyclic system was applied.34 
 
 
Figure 3.15. COSY and key HMBC cross-peaks detected for compound (9a) 
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This method is based on the combined analysis of the coupling constants 2JC,H (in systems 
1H-C-13C-X, related to the dihedral angle between the proton and the heteroatom), 3JH,H 
and 3JC,H (both related to conformational parameters through the Karplus rule). The 
original method was proposed for X = OR but it was successively extended also to X = Cl 
and other different electron withdrawing groups.35,36 Since C13 was adjacent to the chiral 
carbon atom C8, and the small value of 3JH-8/H-13 (1.5 Hz) indicated that a dominant rotamer 
(with the two protons in a gauche orientation) existed around the C8/C13 axis, our 
molecule appeared to possess all the requirements essential for application of the 
Murata’s method.34 We qualitatively determined the four required heteronuclear coupling 
constants through an analysis of the phase-sensitive PS-HMBC spectrum and the obtained 
J data indicated a threo stereochemical relationship between C8 and C13 in compound 9a 
(Fig. 3.16).  
 
Figure 3.16. Application of the Murata method to the C8-C13 axis of compound (9a) 
 
Consequently, on the basis of the known S configuration assigned at C8 for 9, we deduced 
R configuration at C13 of 9a. 
Small amounts of the epimer at position 13, 9b (C18H35ClO4 by HR-EIMS), were also 
obtained. This molecule was easily identified on the basis of the broad similarities among 
its 1H and 13C NMR spectra and corresponding spectra of 9a. The planar structure and 
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signal assignment were then unambiguously deduced on the basis of 2D NMR spectral 
(COSY, HSQC, HMBC) data. Since the small differences between the two series of NMR 
data are restricted to C/H resonances bordering with position 13, we confidently assigned 
the stereostructure of 9b as the epimer of 9a at the newly created chiral center C13. The 
reaction affording 9a and 9b is not stereospecific, however it produces 9a in consistently 
higher amounts (about 6:1).  
Reaction with FeCl2 was then repeated for 8 in the same conditions (solv. CH3CN/H2O 4:1; 
r.t.; 2 hours) previously employed for 9 yielding only two major products, 8a and 8b, in ab. 
2:1 relative yields. Determination of the complete stereostructures of these products 
proved to be quite simple, indeed, the structure of compound  8a, C18H33ClO4 by HR-EIMS, 
was assigned on the basis of the absolute identity of its spectroscopic data (*α+D, 
1H NMR, 
13C NMR) with those of plakortether C, a natural analogue of plakortin that we isolated 
some years ago from Plakortis simplex and whose complete absolute stereostructure was 
established.37   
Compound 8b showed the same molecular formula and very similar 1H and 13C NMR 
spectra compared to 8a. Investigation of 2D NMR spectra (COSY, HSQC, HMBC) of 8b 
indicated that this molecule must possess the same planar structure of 8a; thus, as for 9, 
the reaction produced a mixture of diastereomers. Inspection of the ROESY spectrum of 
8b disclosed a cis relationship between H-9 and H3-15, identical to that of compound 8a. 
Therefore, the difference between compounds 8a and 8b must reside on the configuration 
at C-10 and consequently, compound 8b was identified as the epimer at C-10 of 8a.  
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Figure 3.17. Mechanism hypothesized for the formation of compounds 8a and 8b upon 
reaction of plakortin (8) with FeCl2 
 
The above described computational and experimental investigations completely agree in 
suggesting the possible steps connecting the interaction Fe(II)heme/plakortin [or 
Fe(II)heme/dihydroplakortin] with the death of the parasite. In addition, obtained results 
stimulate some interesting considerations about the mechanism of antimalarial action of 
plakortins and related simple 1,2-dioxanes. The formation of the products 8a/8b obtained 
upon reaction of 8 with FeCl2, can be interpreted only by assuming the preferential 
formation of the oxygen radical at O1 (Fig. 3.17) in agreement with anticipation of 
computational calculations. In addition, the formation of O1-C9 linkage indicates that the 
O1 radical tends to react with the “western” side chain double bond, giving the 
consequent formation of the carbon radical at C10. Interestingly, the obtainment of a 
single configuration at C9 suggests that the reaction proceeds through a concerted 
mechanism, where the following events occur in a single step: 1) electron uptake from 
iron, 2) O1-O2 bond breaking with consequent O1 radical formation, 3) O1-C9 bonding 
with consequent C-10 radical formation.  
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This latter species represents the key toxic intermediate responsible for plakortin 
antimalarial activity and it is involved in a subsequent intermolecular reaction. These are 
valuable insights for the design of new derivatives since this reaction mechanism implies 
that the structure must simultaneously orientate all intramolecular reaction partners in 
order to trigger production of the toxic carbon radical. These results are in agreement with 
our previous conclusions that the lower activity of plakortins compared to artemisinin 
could be also attributed to the marked difference in the conformational behavior 
exhibited by these molecules .  
In the experimental model, C10 carbon radical reacts to give the chlorine-linking mixture 
8a/8b (Fig. 3.17). The formation of this diastereomeric mixture evidenced that the 
chlorination was not concerted with the electron transfer reaction leading to formation of 
C10 radical. Also in the case of dihydroplakortin (Fig. 3.18), the obtained products suggest 
that the endoperoxide bond cleavage produced preferentially an oxygen radical at O1. In 
addition, products 9a/9b indicate a selective involvement of C13 hydrogen atoms in the 
subsequent rearrangement which, most likely, takes place through a 1,5-H shift with 
formation of a carbon radical at that position. Then, the diastereoisomeric mixture of 
products 9a/9b was formed upon chlorination at C13. As a consequence, in the case of 9, 
the C13 carbon radical should be the toxic intermediate responsible for the antimalarial 
activity.  
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Figure 3.18. Mechanism hypothesized for the formation of compounds 9a and 9b upon 
reaction of dihydroplakortin (9) with FeCl2. 
 
Data about the exact mechanism going from carbon radicals of both plakortin (at C-10) 
and dihydroplakortin (at C13) to the corresponding chlorinated species are not available. A 
plausible hypothesis is a “chloro-Fenton” reaction involving direct abstraction of a chlorine 
atom linked at the Fe(III) center, recently proposed in a similar case.38 
The observation of a diastereomeric mixture of chlorinated products, both for 8 and 9, 
supports the availability of the formed carbon radicals (i.e., C10 and C13, respectively) for 
intermolecular reactions. These carbon radicals may exert their toxicity through direct 
reaction with plasmodium biomolecules (e.g., FV membrane lipids, heme, protein 
residues, glutathione), not requiring molecular oxygen to induce the oxidative stress in the 
parasite. The key role of carbon radicals, available for intermolecular reactions, is also 
supported by the behavior of artemisinin and derivatives, where steric hindrance 
significantly affecting carbon radical reactivity has a negative impact on antimalarial 
potency. 22,26 
Another remarkable outcome of our experiments is the complete absence (or 
undetectable presence) of cleavage products, upon reaction of 9 and 8 with FeCl2. Indeed, 
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following the mechanism of oxygen radical evolution described for artemisinin derivatives 
(Fig. 3.10)28,34  the formation of the carbon-carbon cleavage products, could be 
hypothesized. Thus, the absence of the postulated ketone derivatives as well as of 
products which could derive from the rearrangement/reaction of the postulated primary 
carbon radicals indicated that, at least in our experimental conditions, the cleavage 
mechanism does not operate for 8 and 9. In this regard, it is interesting to notice that 
peroxyketal derivatives, structurally related to plakortin [e.g. compound 22,39 (Fig. 3.19), 
have been reported to produce, upon reaction in similar experimental conditions (FeSO4 in 
aqueous solution), mostly cleavage products (Fig. 3.19).40 Given the wide similarity 
between the two carbon scaffolds, the marked difference between the products obtained, 
upon reaction with ferrous ion, is a clear evidence that minor differences in the 
functionality pattern of a 1,2-dioxane [e.g. the presence of a peroxyketal in 22] can result 
into dramatic differences in the evolution of the oxygen radicals.  
 
 
Figure 3.19. FeSO4 induced cleavage of compound 22 
 
The results of our combined studies on plakortin and dihydroplakortin evidenced that 
plakortin alkyl chain double bond reactivity likely support carbon radical formation, on the 
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other hand, the weaker side chain reactivity of dihydroplakortin is balanced by favorable 
conformational parameters. This accounts for the comparable antimalarial activity of the 
two compounds (Table 1), despite the structural differences in their alkyl chains. 
The results of this investigation, in agreement with previously reported SAR, also 
evidenced that the ester side chain is not directly involved in the formation of carbon 
radical intermediates, nevertheless, our docking results demonstrated that the presence 
of ester group may play a role in the interaction with iron, affecting endoperoxide 
approach to heme. Thus, the presence of iron-coordinating groups, other than the 
endoperoxide functionality, must be taken into consideration for the design of new  
plakortin-like antimalarials.  
In summary, the mechanism of action of plakortin-based antimalarials involves the 
formation of an oxygen radical and its "through space" rearrangement to give a carbon 
radical centered on the “western” alkyl side chain, which is the toxic intermediate able to 
directly react with parasite biomolecules. Moreover, the following minimal structural 
requirements, necessary for the activity of this class of antimalarial agents, were identifie: 
1) a 1,2 dioxane ring able to react with Fe(II) species through its endoperoxide group and 
to form an oxygen radical; 2) a side chain bearing possible partners for a “through space” 
intramolecular radical shift from the oxygen to a carbon atom, 3) a conformational 
preference for the conformer which allows the correct orientation of all the 
intramolecular reaction partners, and iv) the formation of a carbon radical amenable of 
intermolecular reactions. On these bases, a 1,2-dioxane ring side chain combining good  
reactivity (such as in plakortin) with  favorable conformational preference (such as in 
dihydroplakoritn) should improve antimalarial activity.  
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3.4. Isolation of new endoperoxide derivatives from an Indonesian Plakortis 
sp. 
In the course of an ongoing screening for bioactive secondary metabolites from 
Indonesian marine invertebrates,41, 42 a specimen of Plakortis sp. collected in the Bunaken 
Marine Park of Manado (North Sulawesi, Indonesia) was analyzed. From the organic 
extract of this sponge we four new peroxyketal polyketides, named manadoperoxides A-D 
(23-26) (Fig. 3.20), have been obtained.  
 
Figure 3.20.  Chemical structures of manadopreoxides A (23), B (24), C (25) and D (26). 
 
The isolation of these endoperoxide derivatives represented an attracting opportunity to 
extend the structure-antimalarial activity relationships previously established for the 
plakortin family. Thus, evaluation of their in vitro antimalarial activity was also carried out.   
The sponge Plakortis sp. (order Homosclerophorida, family Plakinidae) was collected in 
January 2008 along the coasts of the Bunaken island in the Bunaken Marine Park of 
Manado. After homogenization, the organism was exhaustively extracted, in sequence, 
with methanol and chloroform. The combined extracts were subjected to chromatography 
over silica column followed by repeated column and HPLC chromatographies (n-
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hexane/EtOAc mixtures) to afford manadoperoxides A-D (23-26) in the pure state. A small 
piece of the Plakortis sp. was also extracted with EtOH and, following the same 
chromatographic procedure, small amounts of manadoperoxides A-D were also obtained. 
This results rules out a possible role of the extraction solvent on the formation of the 
methoxylated manadoperoxides (see below). 
Manadoperoxide A (23) showed pseudomolecular ion peaks at m/z 327 [M + H]+ and 349 
[M + Na]+ in the positive ESI mass spectrum, while HR measurements assigned to 23 the 
molecular formula C18H30O5, implying four unsaturation degrees. Analysis of 
1H and 13C 
NMR spectra of 23 (CDCl3, see Tables in Suporting Data), guided by inspection of the 2D 
HSQC experiment, revealed the presence of two sp3 methines (one of which is 
oxygenated: δH 4.43, δC 80.1), five sp
3 methylenes, two double bonds [one trisubstituted 
(δH 5.44, δC 124.8; δC 133.3) and one disubstituted (δH 6.03, δC 135.8; δH 5.47, δC 126.0)], 
and five methyls (two of which are methoxy groups: δH 3.72, δC 52.2; δH 3.25, δC 48.8). The 
two remaining unprotonated carbon atoms (δC 171.9 and 103.4) were attributable to an 
ester and to a ketal group, respectively.  
The COSY spectrum of 23 disclosed the sequential arrangement of proton resonances 
indicating the presence of three spin systems [A-C, depicted in bold in (Fig. 3.21)]. The first 
one (A) encompasses a methyl-branched C4 chain (from C-2 to C-5); the second spin 
system (B) builds up a C5 unbranched chain starting from the disubstituted double bond, 
while the third spin system (C) includes only an sp2 methine coupled to a methyl group. 
These moieties were connected through interpretation of the 2D HMBC spectrum [key 
2,3JCH correlations are depicted in (Fig. 3.21)].   
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Figure 3.21. COSY and key HMBC cross-peaks detected for manadoperoxide A (23) 
 
In particular, cross-peaks of H3-14 with C-12, C-13 and C-14 allowed the joining of moieties 
B and C through C-13; analogously, the cross-peaks of H2-5, of H2-8 and of the oxymethyl 
group resonating at δH 3.25 with the ketal carbon resonating at δC 103.4 established C-6 as 
the connection point for moieties A and B. Furthermore, the ester carbonyl (δC 171.9) was 
placed at C-1 on the basis of its HMBC correlations with H2-2 and H-3. Finally, the presence 
of an endoperoxidic bond connecting C-3 and C-6, accounting for the remaining 
unsaturation degree of the molecular formula, was supported by 13C NMR resonances at 
δC 80.1 (C-3) and 103.4 (C-6), typical values for oxygenated carbons belonging to 
endoperoxyketal rings. 43  
The E geometry of the double bond Δ11 was deduced from the large vicinal coupling 
constant JH-11/H-12 = 15.9 Hz. On the other hand, the spatial proximity (evidenced through a 
ROESY spectrum) between H-12 and H-15 indicated the E geometry of the double bond 
Δ13(15). The ROESY spectrum (Fig. 3.22) allowed us also to define the relative orientation of 
the three stereogenic carbons belonging to the six-membered ring.  
 
 
Figure 3.22. Key ROESY cross-peaks detected for manadoperoxide A (23) 
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Particularly informative were the ROESY cross-peaks of H-4 with OMe-6 and of H-5ax with 
H-2a. The trans equatorial-axial orientation of H-3/H-4 was also supported by the low 
value of the vicinal coupling constant JH-3/H-4 = 3.0 Hz. 
The determination of absolute configuration at the three stereogenic centers of 
manadoperoxide A was accomplished through application of the modified Mosher’s 
method44 on a semisynthetic derivative (Fig. 3.23).  
 
 
Figure 3.23. Application of the modified Mosher’s method for determination of absolute 
configuration at C-3 of manadoperoxide A 
 
Thus, reductive cleavage (Zn/AcOH) of the endoperoxide bond of 23 yielded the 
hydroxyketone derivative 27 (present in equilibrium with the cyclic hemiketal forms), 
which was allowed to react with R- and S-MTPA chloride to obtain the corresponding S- 
and R-MTPA esters (28a and 28b), respectively. Analysis of the ∆δ(S – R) values of the 
MTPA esters according to the Mosher’s model indicated the S configuration at C-3. On the 
basis of the previously determined relative configuration, a 3S,4S,6R configuration was 
assigned to manadoperoxide A. 
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Interestingly, Scheuer and coworkers reported from a Plakortis sp. collected near Manado, 
in the same area of our specimen, the isolation of manadic acid A,45 a diastereomer of 
manadoperoxide A differing only for the configuration at C-6. It should be noted that 
manadic acid or its esters were completely undetectable in the organic extract of our 
Plakortis sp., and, thus, apparently, the two different Plakortis sp. specimens elaborate the 
same secondary metabolite but with opposite configuration at a single carbon atom. A 
similar case, involving a different class of marine metabolites, has been recently reported 
by Crews and coworkers, 46 who discovered distinct Theonella swinhoei populations 
producing either 2S-motuporin or 2R-motuporin. In our opinion, these intriguing 
observations would be worthy of further investigations.    
Three additional manadoperoxides (B-D, 24-26) were isolated from the organic extract of 
Plakortis sp. and their stereostructural elucidation followed the same spectroscopic 
approach above detailed for 23, including analysis of 1D and 2D NMR (COSY, HSQC, HMBC, 
ROESY) spectra. The complete assignment of proton and carbon resonances is reported in 
the Experimental Section. For brevity, in the following discussion, I will highlight only the 
significant differences between each of these molecules and manadoperoxide A. These 
differences are restricted to the length and/or functionalization of the “western” alkyl 
chain, and, accordingly, their H/C resonances from positions 1 to 9 resulted to be almost 
coincident to those of 23. Furthermore, ROESY cross-peaks obtained for 24-26 confirmed 
that also the relative configuration around the six-membered ring is identical to that of 
compound 23. Due to the limited amount available for manadoperoxides B-D, partly 
employed also for biological tests, the absolute configurations at C-3/C-4/C-6 of 24-26 
have not been determined; their structures have been drawn extending those above 
deduced for manadoperoxide A. In the case of manadoperoxide D (26), we preferred to 
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employ an aliquot of the sample to determine the absolute configuration of side chain 
stereocenters (see below).  
Manadoperoxide B (24), C19H32O5 by HRMS, contained only an additional methylene group 
compared to compound 23. This group was easily located at C-16 (δH 2.09; δC 21.9) on the 
basis of the vicinal couplings of H2-16 with both H-15 (δH 5.40, t) and the methyl H3-17 (δH 
1.00, t). Also in this case, the ROESY cross-peak H-12/H-15 indicated the E geometry of the 
double bond Δ13(15) .   
Manadoperoxide C (25), C16H26O6 by HRMS, showed a shortened side chain compared to 
compound 23. Inspection of 1H, 13C NMR and 2D NMR COSY spectrum of 25 indicated the 
presence of a single double bond, located at the terminus of the five-carbons spin system 
starting with H2-8. The relatively low field resonances of H-11 (δH 6.78) and H-12 (δH 6.18) 
and the presence of a carbonyl resonance at δC 198.7, in the 
13C NMR spectrum of 25, 
suggested the presence of a conjugated ketone group. This was supported by the 2,3J 
HMBC cross-peaks of the relatively downfield shifted methyl singlet at δH 2.25 both with 
the ketone carbonyl (C-13) and with C-12. The coupling constant JH-11,H-12 = 16.4 Hz was 
indicative of the trans geometry of ∆11,12. 
The molecular formula of manadoperoxide D (26), C18H32O7 by HRMS, indicated the 
presence of two additional oxygen atoms compared to compound 23. 1D NMR spectra of 
26, analyzed with the help of 2D NMR COSY and HSQC spectra, disclosed the arrangement 
of the proton multiplets of the “western” side chain within two spin systems (Fig. 3.24), 
comprising two oxygenated methines.  
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Figure 3.24. COSY and HMBC correlations detected for manadoperoxides C (25) and D (26) 
 
The first spin systems spans from H2-8 to the single sp
2 methine H-12 (δH 5.45, δC 127.1), 
and includes an oxymethine at position 11 (δH 4.40, δC 70.1); the second spin system 
includes only the second oxymethine (δH 4.22, δC 72.8) coupled with a methyl group (δH 
1.27, δC 17.9). The HMBC cross-peaks of H3-14 with C-12, C-13 and C-15 determined the 
connection for the above moieties, thus defining the gross structure of the “western” side 
chain for manadoperoxide D. The spatial proximity of H3-14 with H-11 (ROESY cross-peak) 
indicated the E geometry of the side chain double bond.    
The absolute configurations at the two stereogenic carbons C-11 and C-15 of 26 were 
determined through application of the Riguera method for 1,n-diols.47 To this aim, two 
aliquots of 26 were allowed to react with R- and S-MTPA chloride, obtaining the diesters 
29a and 29b, respectively (Fig. 3.25). Positive ∆δ (S – R) values for protons going from H-10 
to H-16 indicated, according to the Riguera model47 the 11S, 15S configuration.   
 
Figure 3.25. Application of the Riguera’s model for determination of side chain absolute 
configuration in mandaoperoxide D (26) 
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The endoperoxide derivatives 23-26 were assayed in vitro against D10 (chloroquine 
sensitive, CQ-S) and W2 (chloroquine resistant, CQ-R) strains of Plasmodium falciparum 
using the pLDH assay. Obtained results (compiled in Table 2) evidenced a moderate 
antimalarial activity (low μM range) against both CQ-R and CQ-S P. falciparum clones for 
the four manadoperoxides 23-26. The variations in the side chains cause slight, but 
significant, differences in the antimalarial activity, with manadoperoxide C (25) being the 
most active compound of the series. Furthermore, the IC50 values of 23-26 against the CQ-
R strain were almost the half (higher efficacy) of those against the CQ-S strain, as already 
found for artemisinin and plakortin analogues. 11,1 
Table 3.2. In vitro antimalarial  activity of manadoperoxides A-D 
 (23-26), against D10 (CQ-S) and W2 (CQ-R) strains of P. falciparum. 
 D10 
IC50 μM 
W2 
IC50 μM 
23   6.88  0.37 3.74  0.92 
24   6.76  0.32 3.69  0.88 
25   4.54  0.66 2.33  0.48 
26 10.38  0.76 7.93  0.68 
Chloroquine   0.043  0.006         0.65  0.09 
Data are means  SD of four different experiments in triplicate 
 
The modest antimalarial activity of manadoperoxides is particularly surprising for example 
upon comparison of manadoperoxide B (24) with peroxyplakoric B3 ester (30), (Fig. 3.25)
43.  
 
Figure 3.26. Comparison of structures and activities of manadoperoxide B (24) and 
peroxyplakoric B3 (30) ester 
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In spite of the very small structural differences (a methyl group linked at C-2, in 30, in 
place of C-4, in 24), compound 30 exhibited a 56-times higher in vitro antimalarial activity 
compared to 24.48 However, this unexpected difference can be rationalized on the basis of 
our recently published model for the antimalarial activity of 1,2-dioxanes.1  
Briefly, the presence of a methyl at C-4 on the dioxane ring of manadoperoxides induces a 
preferential chair B conformations were two groups are in axial positions. This implies that 
the approach of manadoperoxides to heme iron is complicated (if not prevented) by the 
orientation of groups on the dioxane ring. Of course, this problem is not present for 
compound 30, thus highlighting the impact on antimalarial activity also of subtle structural 
changes.  
 
3.5. Synthesis of simplified antimalarial endoperoxides  
As reported in the previous paragraphs, the isolation of plakortin analogues from Plakortis 
simplex2 and related sources and the preparation of a series of semi-synthetic plakortin 
derivatives1 provided information about the structural requirements of these simple 1,2-
dioxanes for exhibiting antimalarial activity. These results confirmed the crucial role of the 
endoperoxide functionality (the plakortin diol is completely inactive), suggested the 
importance of the “western” alkyl side chain and revealed conformation-dependent 
features critical for antimalarial activity.1 
In a preceding paragraph,21 using a combined chemical and computational approach, I 
have described our results on the possible mechanism of antimalarial action for molecules 
belonging to the plakortin family. This investigation resulted in the proposal that, upon 
interaction with the Fe(II) (likely heme) center, and consequent formation of an oxygen-
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centered radical (preferentially O1), a simultaneous “through space” 1,4 or 1,5 
intramolecular radical shift to a western side chain carbon takes place. This yields to the 
formation of carbon radicals at the “western” side chain which should be the toxic species 
responsible for the antimalarial activity through intermolecular reactions with unidentified 
plasmodium macromolecular targets. Thus, accessibility of endoperoxide oxygens to the 
reactive iron species and correct orientation of O1 with respect to reaction partners for an 
intramolecular radical shift, are essential requirements of the bioactive conformation.  
 
 
Figure 3.27. The simplified plakortin scaffold 
 
Basing on these results, I have designed and accomplished the synthesis of simplified 
plakortin analogues, which have been evaluated for their antimalarial activity. A simplified 
plakortin molecular scaffold, including only the essential pharmacophoric portions, should 
include (Fig. 3.27): 1) a dioxane ring; 2) a monosubstitution at position 3; 3) a mono- or 
disubstitution at position 6, which should guarantee the presence of an alkyl chain long 
enough to provide a partner for the above described intramolecular shift.  
 
Figure 3.28. Schematic photo-oxygenation of 1,3-butadiene derivatives 
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The need for an easy and cheap synthesis directed our interest toward the singlet oxygen 
addition to 1,3-butadiene derivatives for the construction of the endoperoxide ring, the 
critical step of the synthetic procedure. This reaction, depicted in figure 3.29, yields 3,6-
disubstituted 1,2-diox-4-ene derivatives and occurs readily for acyclic conjugated dienes.49 
The mechanism of this reaction has been investigated in detail50,51  and some aspects are 
worthy of being noted: 1) As shown in figure 3.28, the relative configuration of the 
product is directly dependent from the geometry of the reagent as a consequence of a 
pseudo-concerted mechanism of reaction.50 2) For reactions with butadienes, the 
dienophilic reactivity of 1O2 surpasses the other two possible modes of reaction, which 
would afford hydroperoxides (even if allylic hydrogen atoms are present) and 1,2-
dioxetanes. 3) This reaction requires a cisoid conformation of the butadiene derivative and 
the E,E isomer reacts faster than the E,Z and Z,Z isomers. This is likely the result of 
differences in the planar cisoid/transoid conformational equilibrium. The planar transoid 
conformation is predominant for all the butadiene derivatives, but the energy differences 
between the cisoid and transoid conformations are significantly different due to steric 
constraints associated with each isomer. 4) Substituents R and R’ (Fig. 3.28) should not be 
electron-withdrawing groups. In this regard, it has been already reported that the ethyl 
ester of E,E-2,4-hexadienoic acid is practically inert to sensitized photooxygenation.52 In 
the design of the present synthetic project we have experimentally verified that the same 
is true for E,E-2,4-alkadienal derivatives (e.g. E,E-2,4-nonadienal) and for E,E-alka-3,5-dien-
2-one derivatives.  
On the basis of this available information, I planned to utilize the photo-oxygenation of 
E,E-alka-3,5-dienoic acid esters, where the double bond system is not conjugated with the 
carbonyl group.  A literature search revealed that the Ragoussis’ modified Knoevenagel 
Chapter 3                                                                                              Antimalarial Endoperoxides 
 
 59 
condensation could be fruitfully exploited for our needs.53,54 The most important features 
of this reaction are: 1) the non-basic solvent (DMSO), 2) the addition of catalytic amounts 
of piperidinium acetate. The combined effect of both these changes is a minimization of 
the decarboxylative elimination of water, which occurs in the normal Knoevenagel 
mechanism, while the dehydration of the hydroxylated intermediate to a non-conjugated 
β,γ-unsaturated dicarboxylic derivative is favored. The final decarboxylation of this 
intermediate yields an ester of alk-3-enoic acid (Fig 3.29).   
 
Figure 3.29. Schematic description of the Ragoussis’ modified Knoevenagel reaction 
 
Thus, the commercially available trans-2-nonenale (31) was allowed to react with ethyl 
hydrogen malonate in DMSO at 85 °C for 4 hrs in the presence of catalytic amounts of 
piperidinium acetate (Fig. 3.30). After work up, the mixture of obtained dienyl esters was 
further purified through repeated HPLC and argentation chromatography, to obtain ethyl 
Chapter 3                                                                                              Antimalarial Endoperoxides 
 
 60 
undeca-3E,5Z-dienoate (33), ethyl undeca-3E,5E-dienoate (34), and trace amounts of the 
conjugated derivative 32, in the pure state.  
Compound 34 was then subjected to photo-oxygenation reaction using methylene blue as 
photo-sensitizer. A solution of 34 and methylene blue in chloroform was irradiated under 
an oxygen atmosphere with a halogen lamp (500W) for 8 hrs at -20 °C to afford in high 
yields the endoperoxide derivative 35. Given the laborious chromatographic procedure 
necessary to obtain the diene derivative 34 in the pure state, we attempted the photo-
oxygenation reaction on the crude dienyl esters fraction obtained from the above 
modified Knoevenagel procedure. When the mixture was allowed to react in the same 
conditions, we obtained a product which contained a mixture of the unreacted dienes 32 
and 33 and the endoperoxide 35 as a single diastereomer, whose purification proved to be 
particularly simple. This outcome is in perfect agreement with the above reported order of 
reactivity for dienyl esters: E,E (non-conjugated) > Z,E (non-conjugated) >> E,E 
(conjugated). Of course, in the search of an economically affordable procedure for the 
synthesis of simple antimalarial dioxanes, the elimination of a complex and low-yielding 
chromatographic step, is a particularly appreciated result.   
 
Figure 3.30. Synthesis of the endoperoxide 35 
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Then, taking advantage of the reactivity of both the ester and the endocyclic double bond 
groups, a series of derivatives of the endoperoxide 35 were prepared. Starting from 
modifications at the ester group (Fig. 3.31), following parallel reaction conducted for 
plakortin,2 selective ester reduction to the corresponding alcohol 36 was accomplished 
with the use of  LiBH4. Standard acetylation of 36 gave the corresponding ester 37, while 
LiOH-mediated hydrolysis of the ester group afforded the carboxylic acid derivative 38 in 
good yield. Interestingly, attempts of obtaining reaction of the ester group with an 
organometallic reagent (butyl magnesium bromide) afforded, exclusively, attachment of 
the butyl group at one of the endoperoxide oxygen atoms, with consequent cleavage of 
the endoperoxide bond and formation of the ether derivative 39.     
 
 
Figure 3.30. Compounds prepared upon reaction of endoperoxide 35 at the ester center 
 
Subsequently, reactions at the double bond of 35 afforded derivatives shown in Figure 
3.31. Compound 35 was initially subjected to a K2OsO4-mediated dihydroxylation reaction, 
following a recently reported procedure aimed at asymmetric sugar synthesis.13 This 
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reaction produced, almost exclusively (> 99%), the single diastereomer 40 (structure and 
stereochemistry assigned through 2D NMR spectroscopy), as a racemic mixture. This 
compound is formed by anti addition of the 1,2-diol unit with respect to the substituents α 
to the peroxide linkage, as a result of the tendency of the hydroxylation reagent to add 
from the least hindered face. Compound 40 proved to be relatively unstable at room 
temperature and was kept at 0 °C.   
Treatment of 35 with m-CPBA in CH2Cl2 afforded, in high yields, a mixture of two 
compounds, which were purified through normal-phase HPLC. Extensive use of 1D and 2D 
NMR spectroscopy (particularly of ROESY experiment for the stereochemical assignment) 
allowed the identification of the diastereomeric epoxide derivatives 41 and 42, 
corresponding to the products of the two possible approaches of the epoxidizing reagent 
to the double bond. Of course, both compounds were obtained as racemic mixtures. 
Analogously, bromination at the double bond afforded the two diastereomeric racemic 
mixtures 43 and 44.   
 
 
Figure 3.31 Compounds prepared upon reaction of endoperoxide 35 at the endocyclic     
double bond 
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Finally, we attempted chemoselective reduction of the double bond. Diimide-mediated 
reduction appeared to be the best candidate reaction to accomplish this transformation. 
Unfortunately, all our attempts, including in situ generation of diimide in different 
conditions, proved to be unfruitful. While diimide reduction has been reported  for 
dioxene derivatives embedded in bicyclic systems,14,15 as those deriving from singlet 
oxygenation of 1,3-cycloalkadienes, the same reaction is practically ineffective for simple 
monocyclic dioxene derivatives.  
All the synthetic derivatives prepared in the course of this study have been evaluated for 
in vitro antimalarial activity against D10 (chloroquine-sensitive) and W2 (chloroquine-
resistant strains). Obtained results, reported in (Table 3.3), deserve interesting comments.  
Table 3.3. In vitro antimalarial  activity of compounds 35-44 against  
D10 (CQ-S) and W2 (CQ-R) strains of Plasmodium falciparum. 
 D10 
IC50 μM 
W2 
IC50 μM 
35   1.20  0.21 1.49  0.22 
36 Inactive Inactive 
37 21.90  1.33      12.50  2.51 
38   3.33  0.68 3.42  0.56 
39 Inactive Inactive 
40 Inactive Inactive 
41    22.10  6.55       10.30  3.21 
42 Inactive Inactive 
43   8.15  1.34 5.11  0.98 
44   9.12  0.88 5.65  1.22 
Chloroquine   0.11  0.01 1.39  0.25 
 Data are means  SD of four different experiments in triplicate 
Inactive means IC50 > 30 μM 
 
The most active compound of the series is compound 35, which showed a quite good 
antimalarial activity (low µM range, about one half of the plakortin potency) on both 
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strains of P. falciparum. On the contrary, all the synthetic derivatives prepared from 35 
proved to be less active than their parent compound, but in different extent. While the 
inactivity of 39 was expected on the basis of its lack of the endoperoxide bond, it is 
interesting to notice the marked decrease of activity caused by reduction of the ester 
group, dihydroxylation and epoxidation of the double bond. On the other hand, although 
still causing a decrease in the pharmacological activity, bromination and hydrolysis of the 
ester group appeared to be better tolerated. 
In conclusion,  basing on the plakortin pharmacophore, I have prepared a good 
antimalarial compound starting from commercially available material and using a 
sequence of two easy and cheap reactions. All the attempted modifications on the 
molecular scaffold of 35 caused a decrease in the pharmacological activity. However, a 
number of different “long” alkyl chains could be prepared by starting from a different α,β-
unsaturated aldehyde.  
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CHAPTER 4- FURTHER SECONDARY 
METABOLITES FROM MARINE ORGANISMS 
 
4.1. Theonella swinhoei3 
Taking advantage of the official agreement established between the University Federico II 
of Naples and the University of Sam Ratulangi of Manado ( Indonesia), we have the 
opportunity of participating to an annual expedition along the coasts of Bunaken Islands, 
Manado (Indonesia). During this expeditions, a number of marine invertebrates are 
collected to be annalyzed for their chemical composition and biological activity of the 
secondary metablites. In the frame of this project,58 I had the opportunity to examine a 
specimen of Theonella swinhoei collected along the coasts of Manado (North Sulawesi, 
Indonesia). 
Marine sponges belonging to the genus Theonella (Lithistida, Theonellidae) are remarkably 
prolific sources of structurally intriguing and diverse secondary metabolites, which have 
been calculated to represent more than nine biosynthetic classes.59 These include non-
ribosomal peptides with promising biological activities (as the antifungal theonellamides,60 
the cytotoxic polytheonamides,61 and the antiviral papuamides62), complex polyketides as 
swinholide A,63 and tetramic acid glycosides as aurantosides.64 There is a continuing 
speculation that symbiotic microorganisms could be the true producers of many of these 
compounds. This hypothesis has been convincingly supported in the cases of swinholide A 
and onnamides: the former has been isolated from two field collections of marine 
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cyanobacteria,65 while the involvement of symbiotic microorganisms in the production of 
the latter has been demonstrated through the isolation of the biosynthetic gene cluster 
from the complex metagenome of the sponge.66 
A specimen of the sponge Theonella swinhoei was collected by hand in the area of the 
Bunaken Marine Park of Manado and kept frozen until sequentially extracted with 
methanol and dichloromethane by soaking the diced sponge tissue (560 g wet wt.). The 
extracts were concentrated, combined, and then partitioned between ethyl acetate and 
water. The EtOAc-soluble material was chromatographed on silica gel, using a gradient 
solvent system of n-hexane/EtOAc/MeOH. Fractions eluted with n-hexane/EtOAc (3:7) 
were combined and further purified by reverse-phase HPLC to obtain a new chlorinated 
polyene as yellow amorphous solid, which we named aurantoic acid (45) (Fig. 4.1). From 
the less polar fractions of the organic extract, we obtained also and a 4-methylene sterol, 
named dehydroconicasterol (46), together with the known molecules aurantoside G (47), 
conicasterol (48), and theonellasterol (49). 
The electrospray mass spectrum of 45 showed pairs of ions at m/z 225/227 [M + H]+ and at 
m/z 247/249 [M + Na]+, both in ab. 3:1 ratio, suggesting the presence of a chlorine atom. 
The low resolution ESIMS data, along with 1H and 13C NMR data, pointed to a molecular 
formula of C12H13ClO2, indicating six unsaturation degrees, which was confirmed by HR-
MS. The UV-visible spectrum (MeOH) showed absorptions characteristic of a polyene 
system (λmax  346 and 363 cm
-1). The 1H NMR spectrum of 45 (500 MHz, CDCl3) showed the 
signals of a vinylic methyl (δ 2.19, bs) and of nine multiplets in the downfield region (δ 5.8-
7.4). Four of these resonances appeared as well resolved and isolated signals (δ 7.31, 6.54, 
6.26, and 5.86), while two clusters centred around δ 6.62 (two overlapping signals) and 
6.40 (three overlapping signals) were deconvoluted with the aid of 2D NMR experiments. 
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Figure 4.1 Chemical structures of aurantoic acid (45), dehydroconicasterol (46), 
aurantoside G (47), conicasterol (48), and theonellasterol (49) 
 
Careful analysis of the COSY and TOCSY spectra allowed us to build up a single spin system 
going from H-2 to H-10, while the HSQC experiment guaranteed the association of the 
resonances of all these sp2 methines with those of the relevant carbon atoms. In addition 
to the resonance of the methyl at δC 25.3, the 
13C NMR spectrum of 45 showed also the 
signals of two sp2 unprotonated carbons at δC 132.6 and 169.1, respectively. The latter 
resonance could be assigned to a carboxylic group, located at C-1 on the basis of its HMBC 
cross-peaks with both H-2 and H-3. Analogously, the resonance at δC 132.6 should 
necessarily be assigned to the chlorine-linking carbon atom, which was placed at C-11 on 
the basis of its HMBC cross-peaks with Me-12, H-10 and H-9. The trans geometry of the 
four disubstituted double bonds was easily inferred from the coupling constant  values (JH-
2/H-3, JH-4/H-5, JH-6/H-7, JH-8/H-9), ranging from 14.9 to 15.4 Hz. The Z geometry of the ∆
10 double 
bond was deduced from the NOE correlation of H-10 with CH3-12. 
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The extensively conjugated system of aurantoic acid 45, consisting of a sequence of five 
double bonds and one carboxylic acid, make this compound a particularly labile molecule. 
Indeed, we observed that both the storage in moderately acidic solvents, as chloroform, 
and the exposure to light triggered the slow formation of a mixture of products. Although 
the structures of these molecules have not been characterized in detail, partial available 
data suggest the occurrence of extensive trans/cis isomerizations. Indeed, the ESI mass 
spectrum of the mixture showed unchanged molecular ions at m/z 225/227 [M + H]+ and 
at m/z 247/249 [M + Na]+, while its 1H NMR spectrum exhibited a series of new 
resonances in the vinylic region, overlapping to those of the original molecule. 
Aurantoic acid 45 can be viewed as a unique member in the class of naturally occurring 
conjugated polyene derivatives. Interestingly, also the non-chlorinated analogue of 
aurantoic acid (2,4,6,8,10-dodecapentenoic acid) has never been found in nature, while, 
the isomeric 3,5,7,9,11-dodecapentenoic acid was obtained from the insect Llaveia axin.67 
 
 
 
Figure 4.2 The aurantoic acid moiety (highlighted in bold) in the structure of aurantoside G 
and a related dodecenoic acid moiety (highlighted in bold) in the structure of onnamide A 
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Figure 4.2 highlights that a non-chlorinated aurantoic-like subunit is detectable in the 
structure of onnamide A68 and that a chlorinated polyene moiety, clearly reminiscent of 
aurantoic acid, is evident in the structures of aurantosides, particularly of aurantosides G-
H.64 These tetramic acid glycosides have been proposed to derive from a condensation 
reaction between an aminoacid (L-aspartic acid) and a polyene acid, followed by N-
glycosilation.64 Thus, it is interesting to notice that the carbon chain of aurantoic acid (C12) 
lacks one acetate unit compared to the postulated polyene precursor of aurantosides G-H 
(C14) and two acetate units compared to the corresponding precursor of aurantosides A-E 
(C16).
69 
Interestingly, we isolated aurantoside G (47) as a reddish solid from the polar fractions (Si-
fractions eluted with EtOAc/MeOH 9:1) of the organic extract of T. swinhoei, and assigned 
its structure basing on the comparison with literature data.64 Our isolation of aurantoside 
G is in perfect agreement with the Crews proposal for the classification of T. swinhoei 
phenotypes.59 Indeed, sponges belonging to phenotype III, characterized by red-orange 
ectosomes and endosomes (as our specimen), should contain good amounts of 
aurantosides, while non-ribosomial polypeptides and complex polyketides should be very 
scarce or absent. 
After, I turned ur attention to the sterol composition of T. swinhoei. Fractions of the Si-
column eluted with n-hexane/EtOAc (7:3) were combined and subjected to further HPLC 
purification. This procedure allowed us to obtain pure samples of the 4-methylene sterols 
conicasterol (48)70 and theonellasterol (49),70 which represent the major components of 
the sterol fraction of several Theonella species. Careful inspection of the 1H NMR spectra 
of tail fractions resulting from the above purification led us to suspect the presence of an 
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additional sterol showing a different pattern of sp2 methylene proton signals (see Fig. 4.3), 
which was later supported by GC-MS.  
Thus, the peracetylated crude sterol fraction, obtained upon reaction with an excess of 
Ac2O in dry pyridine, was subjected to GC-MS analysis in standard conditions for peracetyl 
sterols. The GC separation evidenced the presence of three peaks, which, on the basis of 
the corresponding mass spectra, were assigned to conicasterol acetate, theonellasterol 
acetate and to a third molecule, whose molecular ion (m/z 452) was two mass units lower 
than that of conicasterol acetate (m/z 454). Unfortunately, all our attempts to completely 
separate the crude fraction, through repeated HPLC on normal and reversed stationary 
phases, also employing different solvent mixtures, proved to be unfruitful. 
                                                                                   
 
 
 
 
 
Figure 4.3. The middle-field region in the 1H NMR spectrum (in CDCl3) of 
dehydroconicasterol (ledt) and of the sterol crude fraction (right) 
 
At this stage, we reasoned that the efficiency of this separation could be significantly 
improved through the use of the so-called argentation silica gel chromatography, a 
technique involving the impregnation of the stationary phase with a silver ion (from 
AgNO3).
71 Since Ag+ ion and alkenes form a strong complex by two-electron/three-center 
bonding, the retention times of molecules differing in the number of double bonds, as the 
yet unidentified sterol and conicasterol likely were, should be sufficiently different.  
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Thus, the sterol crude fraction was chromatographed through a Ag+-impregnated silica gel 
column, eluting with n-hexane/EtOAc mixtures of increasing polarities. As expected, the 
new sterol 46 was eluted after conicasterol and theonellasterol, in pure form.  
Dehydroconicasterol 46 was obtained as an optically active colorless amorphous solid. The 
molecular formula C29H46O, requiring seven degrees of unsaturation, was established 
through NMR data (see Experimental Section) and HRMS. The 13C NMR spectrum of 46 (in 
CDCl3), interpreted with the help of the 2D HSQC experiment, showed the presence of 29 
carbon atoms, including one oxygen-bearing methine carbon (δC 73.4) and six sp
2 carbons, 
four of which were unprotonated (δC 125.7, 142.9, 153.1, 156.8), while the remaining two 
carbons were identified as sp2 methylenes (δC 105.8, δH 4.71 and 4.65; δC 102.8, δH 5.07 
and 4.63). The 1H NMR spectrum of 46 (in CDCl3), in addition to the four broad singlets 
assigned to the sp2 methylene protons, showed two methyl singlets (δH 0.83 and 0.58), 
three methyl doublets (δH 0.96, 1.01 and 1.03), a series of multiplets between δH 1.00 and 
2.50, and a carbinol methine resonance at δH 4.04.  
The COSY experiment allowed the building of the four spin systems indicated in bold in Fig. 
4.4, while a series of HMBC correlations (Fig. 4.4) allowed the connection of these 
fragments and the assembling of dehydroconicasterol (46) structure.  
 
Figure 4.4. COSY and key HMBC correlations detected for dehydroconicasterol (46) 
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Particularly informative were the cross-peaks exhibited by the two methyl singlets Me-18 
and Me-19; moreover, the correlations of H2-29 with C-3, C-4, and C-5 indicated the 
attachment of an sp2 methylene at C-4, while the other sp2 methylene was attached at C-
24 on the basis of the correlations of H2-28 with C-23, C-24 and C-25. Finally, the 
tetrasubstituted double bond was placed at ∆8(14) on the basis of the HMBC cross-peaks of 
both H2-7 and H2-15 with C-8 (δC 125.7) and C-14 (δC 142.9). These data indicated that 46 
was a C29 sterol differing from conicasterol in the presence of an additional double bond 
between C-24 and C-28. Comparison of the 1H and 13C NMR data of 46 (Table 5) with those 
of conicasterol (48)70 provided further support to this assignment and also indicated that 
the two compounds share the same configuration at the common stereogenic carbons. 
Steroids bearing a 4-methylene group are relatively rare metabolites; to date, only five 
papers have been published on 4-methylene steroids from marine organisms.72 This 
unusual group has been proposed to biogenetically arise from a shunt in the oxidative 
demethylation of the 4α-methyl series, through the dehydration of the primary alcohol 
formed in the first oxidation of the methyl group.70 The isolation of dehydroconicasterol 
46 adds an interesting piece to this hypothesis, indeed this compound is the likely 
biogenetic precursor of both conicasterol 48 and theonellasterol 49, which could derive 
from compound 46 through reduction or transmethylation with S-adenosylmethionine, 
respectively.  
In conclusion, the chemical analysis of an Indonesian specimen of the widely studied 
sponge Theonella swinhoei73 yielded two new compounds, aurantoic acid 45 and 
dehydroconicasterol 46, both having a likely biogenetic relationship with well-known 
Theonella metabolites (aurantosides and conicasterol/theonellasterol, respectively).  
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Compounds 45-49 were tested for in vitro cytotoxic activity against three cell lines (C6, 
glioma; HeLa, epithelial carcinoma; H9c2, cardiac myoblast) and they exhibited no 
significant inhibition of the cell growth (IC50 > 70 μM).       
 
4.2. Plakortis simplex74 
As part of an ongoing search for biologically active compounds from marine invertebrates, 
the research group of prof. Taglialatela-Scafati has been devoting considerable efforts to 
the chemical investigation of the Caribbean sponge Plakortis simplex. This research 
project, started about ten years ago, has been strongly fostered by the discovery of a large 
array of structurally unique and biologically active metabolites. This richness of secondary 
metabolite production has been discussed in a review paper75 and has been recently 
correlated to the wide presence of bacterial and fungal symbionts associated to the 
sponge host cells.76 For example, P. simplex provided a series of promising lead 
compounds for drug development, including the immunosuppressive glycolipids 
plakosides77 and simplexides78 and a series of endoperoxide-containing derivatives related 
to plakortin (8) (see previous chapter),79,2 for which a potent antimalarial activity (in the 
nM range) has been discovered.80 Structurally unique metabolites were also disclosed as 
components of the most polar fractions obtained from the organic extracts of P. simplex. 
Indeed, these fractions showed to contain the first natural betaine derivatives to be 
characterized by a iodinated indole ring,81,82 e.g. plakohypaphorine E (50) (Fig. 4.5), and 
the unique 4-alkylpyridinium alkaloid simplakidine (51) (Fig. 4.5).83  
Careful examination of the polar fractions of P. simplex carried out during my PhD course 
yielded to the isolation of a new 4-alkylpyridinium alkaloid that we have named 
simplexidine (52), (Fig. 4.5). 
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Figure 4.5. Compounds from Plakortis simplex, including the new simplexidine (52). 
 
A specimen of the sponge Plakortis simplex (Demospongiae, order Homosclerophorida, 
family Plakinidae) was collected during the summer of 2002 along the coasts of The 
Bahamas and immediately frozen. After homogenization, the organism was exhaustively 
extracted, in sequence, with methanol and chloroform. The methanol layer was 
partitioned between n-BuOH and water, and, subsequently, the organic phase, combined 
with the CHCl3 extract, was subjected to chromatography over a reversed phase (RP18) 
silica column eluted with a solvent gradient from H2O/MeOH 9:1 to MeOH and then to 
MeOH/CHCl3 9:1. The most polar fractions were preliminarily separated over silica gel 
(gradient from EtOAc to MeOH) and then re-chromatographed by reverse-phase HPLC 
(eluent MeOH/H2O 4:6) to finally yield 2.0 mg of pure simplexidine (52). 
The molecular formula C15H21NO2 was assigned to simplexidine ([α]D = –5.8) based on 
mass spectrometry evidence [ESI-MS (negative ions): m/z 246 (M-H)-; ESI-MS (positive 
ions): m/z 248 (M+H)+, 270 (M+Na)+; HR-FABMS: m/z 248.1647 (M+H)+, calcd. for 
C15H22NO2 m/z 248.1651]. 
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The 1H-NMR spectrum of simplexidine (see Experimental Section) showed three signals (a 
singlet at δH 8.81 and two doublets at δH 8.63 and 7.91) in the aromatic region, three 
methine multiplets (δH 5.48, 5.35, and 3.81) and a methyl singlet (δH 4.34) in the midfield 
region, and a series of well resolved signals confined in the spectral region ranging from δH 
2.50 to 0.80, including two methyl triplets at δH 0.93 and 0.89. The presence of an aromatic 
chromophore in the structure of simplexidine (52) was further suggested by the UV 
absorption at νmax 268 nm and by the presence of five signals between δC 127 and 164 in 
the 13C-NMR spectrum. 
The 15 carbon signals present in the 13C-NMR spectrum were assigned, with the aid of 
DEPT experiments, to three methyls, three methylenes, six methines and three 
unprotonated sp2 type carbons. 
Among these latter resonances, the signal at δC 168.6 could be ascribed to a carboxylate 
group, as suggested also by the IR absorption at  νmax 1642 cm-1. Association of the 
resonances of the 12 proton-bearing carbons with those of the relevant protons was 
accomplished through the analysis of a 2D NMR gradient-HSQC spectrum. Inspection of 
the 1H-1H COSY NMR spectrum of simplexidine (52) allowed us to arrange all the proton 
multiplets within the two spin systems showed in red in Figure 4.6.  
The first fragment includes only the two mutually coupled aromatic doublets at δH 8.63 
and 7.91, while the second moiety is an eight-carbon fragment connecting the two methyl 
triplets (from H3-1 to H3-8) and comprising two coupled sp2 methines (H-3 and H-4) and a 
single branching at the sp3 methine C-6 (δH 3.81). 
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Figure 4.6.  1H-1H COSY and key 2,3JC-H HMBC correlations of simplexidine (52) 
 
With these data in our hands and taking into account the molecular formula, the assembly 
of the carbon framework of simplexidine (52) required the elucidation of an aromatic 
C7H6NO2 subunit, probably linked at C-6 and comprising a carboxylate group. 
Interpretation of diagnostic gradient-HMBC cross-peaks (Fig. 4.6) was of pivotal 
importance to resolve this issue and suggested the presence of a disubstituted N-methyl 
pyridinium ring. This assignment was corroborated by perfect agreement of 1H-and 13C-
NMR resonances of this subunit with literature values.83,84  
In particular, the N-methyl singlet at  δ 4.34 (H3-8’) showed g-HMBC cross-peaks with two 
almost overlapped protonated carbons at δC 143.1 (C-2’, H-2’ = δH 8.81, s) and 143.4 (C-6’, 
H-6’ = δH 8.63, d, J = 6.9 Hz). Substitution at C-2’ and C-6’ of the pyridinium ring was 
consequently excluded, and, since considering the doublet nature of H-6’, C-5’ must be 
protonated as well, this leaves only a 3,4 disubstitution as possible. The intense g-HMBC 
cross-peak H-2’/C-7’ suggested the placement of the carboxylate group at C-3’, while the 
cross peaks H-6/C-3’, H-6/C-4’, H-6/C-5’ and H-5’/C-6 confirmed the linkage of the alkyl 
chain at C-4’, thus completely defining the planar structure of simplexidine (52). The 
coupling constant JH-3/H-4 = 15.4 Hz was indicative of the trans geometry of the Δ3,4 double 
bond, while, also considering the limited amounts of sample available (2.0 mg), strategies 
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aimed at the definition of the absolute configuration at the single stereogenic carbon C-6 
were not undertaken. 
Pyridinium alkaloids are frequently isolated from the polar extracts of marine 
invertebrates, mostly sponges; however, in spite of the wide diffusion, the chemical 
diversity within this class of compounds is somewhat limited and only two structural 
groups can be identified. The most common group of pyridinium derivatives includes 
oligomeric structures with alkyl linear chains linked at positions C-3 and N-1 of the 
pyridinium ring, e.g. the recently reported pachychaline C (53) (Fig. 4.7).85 These molecules 
are known to exhibit a range of bioactivities including cytotoxic86 and anti-cholinesterase87 
properties. The second structural group includes the carboxyl-containing homarine (54) 
(Fig. 4.7) or trigonelline (55) (Fig. 4.7) substituted at C-3 or C-2, respectively, with short 
alkyl chains. 
The isolation of simplexidine (52) is particularly remarkable since it confirms the existence, 
within the Plakortis simplex biosynthetic machinery, of enzymes deputed to the 
attachment of polyketidederived carbon chains at the 4 position of pyridinium rings. In the 
case of simplakidine (51), this unique reaction led to the linkage between the trigonelline 
nucleus and a C17 moiety that clearly shared the plakortin (8) carbon backbone. On the 
other hand, the biosynthetic origin of the C8 group present in the structure of simplexidine 
(52) cannot be unambiguously predicted, although similarly to that postulated for 
plakortin derivatives,88 a polyketide origin can be hypothesized also in this case. 
Simplexidine (52) exhibited very weak cytotoxicity toward murine macrophages (RAW 
264-7) with 30% of growth inhibition at 80 μg/mL.  
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Figure 4.7. Chemical structures of pachychaline C (53), homarine (54) and trigonelline (55)
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CHAPTER 5 - EXPERIMENTAL SECTION 
5.1. General Experimental Procedures 
Optical rotations (CHCl3 or MeOH) were measured at 589 nm on a Perkin-Elmer 192 
polarimeter. 1H (500 and 700 MHz) and 13C (125 and 175 MHz) NMR spectra were 
measured on Varian INOVA spectrometers. Chemical shifts were referenced to the 
residual solvent signal (CDCl3: δH 7.26, δC 77.0; CD3OD: δH 3.30, δC 49.0;). Homonuclear 
1H 
connectivities were determined by the COSY experiment; one-bond heteronuclear 1H-13C 
connectivities by the HSQC experiment; two- and three-bond 1H-13C connectivities by 
gradient-HMBC experiments optimized for a 2,3J of 8 Hz . ESI-MS spectra were performed 
on a LCQ Finnigan MAT mass spectrometer. GC/MS analysis was performed on a Focus GC-
Polaris Q (Thermo) with EI (70eV) ionization. A 5% diphenyl 30m x 0.25mm x 0.25 μm 
(Trace TR-5, Thermo) was used, with He as carrier gas. Medium pressure liquid 
chromatography was performed on a Büchi apparatus using a silica gel (230-400 mesh) 
column. In the argentation silica gel chromatography, the silica gel stationary phase was 
impregnated with a solution of AgNO3 in EtOH/H2O, then the liquid was evaporated and 
the silica dried in the oven at 100 °C overnight. HPLC were achieved on a Knauer apparatus 
equipped with a refractive index detector and analytical LUNA (Phenomenex) SI60 or RP18 
(250 × 4 mm) columns. 
5.2. Investigation of the plakortin mechanism of action 
5.2.1 Reaction of dihydroplakortin (9) with FeCl2. Dihydroplakortin (9, 25.0 mg, 0.080 
mmol) was dissolved in CH3CN/H2O 4:1 (5 mL) and freshly purchased FeCl2·4H2O (78 mg, 
0.40 mmol) were added. The reaction mixture was left under stirring at room temperature 
for 2 hours. Light was excluded from the reaction. Then the obtained mixture was 
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partitioned between water and EtOAc. The organic phase, dried over Na2SO4, was purified 
by HPLC (SI60 n-hexane/EtOAc 85:15) affording compounds 9a (15.0 mg, 0.040 mmol, 
50%) and 9b (2.5 mg, 0.0067 mmol, 8%) in the pure state.  
5.2.2. Compound 9a. Colorless oil. *α+D
25 + 35 (c 0.10 in CHCl3). 
1H NMR (CDCl3, 500 MHz): 
δ 4.53 (H-13, dq, J 6.90, 1.5); 4.19 (H-3, m); 3.72 (OMe, s); 2.56 (H-2a, dd, J 16.4, 10.5); 
2.37 (H-2b, dd, J 16.4, 10.5); 1.97 (H-4, m); 1.83 (H-8, m); 1.77 (H-7a, dd, J 14.2, 5.6); 1.67 
(H-5a, dd, J 14.4, 9.0); 1.45 (H3-14, d, J 6.90); 1.39-1.31 (H2-9, H2-10, H2-11, m) 1.31 (H-7b, 
overlapped); 1.29 (H-5b, overlapped); 1.27 (H-16a, overlapped); 1.17 (H3-15, s); 1.16 (H-
16b, overlapped); 0.90 (H3-12, t,  J 7.2). 
13C NMR (CDCl3, 125 MHz): δ 174.6 (C-1); 71.9 (C-
6); 70.8 (C-3); 64.2 (C-13); 51.0 (OMe); 45.1 (C-7); 42.8 (C-5); 41.3 (C-8); 40.1 (C-4); 37.0 (C-
2); 31.2 (C-9); 30.3 (C-10); 26.9 (C-17); 26.4 (C-15); 23.4 (C-11); 23.0 (C-14); 13.4 (C-12); 
12.9 (C-18). ESIMS: m/z 373 and 375 (3: 1) [M + Na]+. EIMS: m/z 350 and 352 (M). HREIMS: 
m/z 350.2229, calcd. for C18H35
35ClO4 m/z 350.2224.  
52.3.Compound 9b. Colorless oil. *α+D
25 + 22 (c 0.10 in CHCl3). 
1H NMR (CDCl3, 500 MHz): δ 
4.58 (H-13, m); 4.19 (H-3, m); 3.72 (OMe, s); 2.56 (H-2a, dd, J 16.4, 10.5); 2.37 (H-2b, dd, J 
16.4, 10.5); 1.97 (H-4, m); 1.83 (H-8, m); 1.77 (H-7, dd, J 14.2, 5.6); 1.67 (H-5a, dd, J 14.4, 
9.0); 1.37 (H3-14, d, J 7.2); 1.39-1.31 (H2-9, H2-10, H2-11) 1.31 (H-7b, overlapped); 1.29 (H-
5b, overlapped); 1.27 (H-16a, overlapped); 1.17 (H3-15, s); 1.16 (H-16b, overlapped); 0.90 
(H3-12, t,  J 7.2). ESIMS: m/z 373 and 375 (3: 1) [M + Na]
+. EIMS: m/z 350 and 352 (M). 
HREIMS: m/z 350.2217, calcd. for C18H35
35ClO4 m/z 350.2224. 
5.2.4. Reaction of plakortin (8) with FeCl2. Plakortin (8, 50.2 mg, 0.16 mmol) was dissolved 
in CH3CN/H2O 4:1 (8 mL) and FeCl2·4H2O (155 mg, 0.80 mmol) were added. The reaction 
mixture was left under stirring at room temperature for 2 hours. Light was excluded from 
the reaction. Then the obtained mixture was partitioned between water and EtOAc. The 
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organic phase, dried over Na2SO4, was purified by HPLC (SI60 n-hexane/EtOAc 9:1) 
affording compounds 8a (27.0 mg, 0.077 mmol, 48%) and 8b (13 mg, 0.037 mmol, 23%) in 
the pure state.  
5.2.5.Compound 8a. Colorless oil. *α+D
25 - 6 (c 0.10 in CHCl3). ESIMS: m/z 371 and 373 (3: 1) 
[M + Na]+. HREIMS: m/z 348.2059, calcd. for C18H33
35ClO4 m/z 348.2067.
 1H and 13C NMR: 
see data reported in ref. 37.  
5.2.6.Compound 8b. *α+D
25 - 13 (c 0.10 in CHCl3). 
1H NMR (CDCl3, 500 MHz): δ 4.32 (H-3, 
m); 3.91 (H-10, m); 3.81 (H-9, m); 3.70 (OMe, s); 2.66 (H-2a, dd, J 16.4, 10.5); 2.36 (H-2b, 
dd, J 16.4, 10.5); 2.22 (H-8, m); 2.06 (H-7a, m); 1.87 (H2-11, m); 1.78 (H-4, m); 1.69 (H-5a, 
dd, J 14.0, 9.0); 1.55 (H-7b, overlapped); 1.51 (H-5b, overlapped); 1.39 (H-16a, m); 1.28 
(H3-15, s); 1.25 (H2-13, m); 1.20 (H-16b, m); 1.06 (H3-12, t, J 7.2); 0.94 (H3-14, t, J 7.2); 0.92 
(H3-17, d, J 6.90). ESIMS: m/z 371 and 373 (3: 1) [M + Na]
+. HREIMS: m/z 348.2070, calcd. 
for C18H33
35ClO4 m/z 348.2067. 
5.3. Isolation of manadoperoxides  
5.3.1. Animal material, extraction, isolation: A specimen of Plakortis sp. (order 
Homosclerophorida, family Plakinidae) was collected in January 2008 along the coasts of 
the Bunaken island in the Bunaken Marine Park of Manado. A voucher sample has been 
deposited at the Dipartimento di Chimica delle Sostanze Naturali, Università di Napoli 
Federico II. After homogenization, the organism was exhaustively extracted, in sequence, 
with methanol and chloroform (dry weight after extraction 199.3 g). The combined 
extracts (8.6 g) were subjected to chromatography over silica column (230-400 mesh) 
eluting with a solvent gradient of increasing polarity from hexane to MeOH. Fractions 
eluted with n-hexane/EtOAc 9:1 were subjected to repeated column and HPLC 
chromatographies (n-hexane/EtOAc 95:5) affording manadoperoxides A (23, 8.5 mg) and B 
Chapter 5                                                                                                          Experimental Section 
 
 82 
(24, 6.2 mg) in the pure state. Fractions eluted with n-hexane/EtOAc 8:2 were re-
chromatogrpahed by HPLC (n-hexane/EtOAc 85:15) to give manadoperoxide C (25, 2.0 
mg). Fractions eluted with n-hexane/EtOAc 3:7 were re-chromatographed by HPLC (n-
hexane/EtOAc 4:6) affording pure manadoperoxide D (26, 3.1 mg). 
5.3.2. Manadoperoxide A: Colorless amorphous solid; [α]D -5.2 (c 0.3, CHCl3); 
1H NMR 
(CDCl3, 500 MHz) see  Table; 
13C NMR (CDCl3, 125 MHz) see Table; (+) ESI-MS m/z 327 [M + 
H]+, 349 [M + Na]+. HR-ESIMS found 327.2177; C18H31O5 requires 327.2171. 
 
a Overlapped with other signals 
5.3.3. Reductive cleavage of manadoperoxide A (23) and reaction with R- and S-MTPA 
chlorides: Compound 23 (5.0 mg, 15.3 μmol) in 100 L of dry ether was treated with 50 L 
of acetic acid and an excess (20 mg) of Zn dust and then stirred vigorously for 24 h at room 
temperature. After confirmation of disappearance of the starting material by TLC, solution 
was neutralized with Na2CO3 and the solid removed by filtration. The solvent was then 
1H (500 MHz) NMR data of manadoperoxides A (23), C (25) and D (26) in CDCl3 
Pos. 23 25 26 
 δH (mult., J in Hz) δH (mult., J in Hz) δH (mult., J in Hz) 
2a 2.97 (dd, 15.5, 9.5) 2.93 (dd, 15.7, 9.6) 2.94 (dd, 15.5, 9.5) 
2b       2.44 (dd, 15.5, 4.5) 2.46 (dd, 15.7, 4.1) 2.46 (dd, 15.5, 4.3) 
3 4.43 (ddd, 9.5, 4.5, 3.0) 4.46 (ddd, 9.6, 4.1, 3.0) 4.44 (ddd, 9.5, 4.3, 3.0) 
4 2.57 (m) 2.56 (m) 2.58 (m) 
5a 1.68a 1.73a 1.68a 
5b 1.28a 1.29a 1.33 
7 0.84 (d, 7.1) 0.85 (d, 7.1) 0.86 (d, 7.1) 
8a 1.66a 1.69a 1.63a 
8b 1.32a 1.30a 1.34a 
9a 1.40a 1.53 (m) 1.42a 
9b 1.40a 1.53 (m) 1.35a 
10a 2.07 (m) 2.25a 1.64a 
10b 2.07 (m) 2.25a 1.55 (m) 
11 5.47 (dt, 15.9, 6.0) 6.78 (dt, 16.4, 6.6) 4.40 (m) 
12 6.03 (d, 15.9) 6.18 (d, 16.4) 5.45 (d, 8.7) 
14 1.70 (bs) 2.25 (s) 1.71 (bs) 
15 5.44 (bq, 6.9)  4.22 (q, 7.1) 
16 1.69a  1.27 (d, 7.1) 
1-OMe        3.72 (s) 3.72 (s) 3.73 (s) 
6-OMe 3.25 (s) 3.27 (s) 3.27 (s) 
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evaporated and the obtained product was partitioned between H2O and CHCl3. The 
organic phase contained ketoalcohol 27 (3.5 mg, 77% yield. An aliquot of 27 (1.0 mg, 3.4 
μmol) was treated with R-MTPA chloride (30 μL) in 400 μL of dry pyridine with a catalytic 
amount of DMAP overnight at rt. Then, the solvent was removed and the product was 
purified by HPLC (n-hexane/EtOAc 97:3) to obtain the S-MTPA ester 28a (1.3 mg, 80% 
yield). When compound 27 (1.0 mg, 3.4 μmol) was treated with S-MTPA chloride, 
following the same procedure, 1.3 mg (80% yield) of R-MTPA ester 28b were obtained.  
5.3.4 (S)-MTPA ester (28a): Amorphous solid. ESIMS (positive ions): m/z 485 [M + H]+. 1H 
NMR (CDCl3): d 7.35 and 7.45 (MTPA phenyl protons), 6.03 (1H, d, J = 15.9 Hz, H-12), 5.65 
(H-3, m); 5.45 (1H, q, J = 6.9 Hz, H-15), 5.42 (1H, dt, J = 15.9, 6.0 Hz, H-11), 3.72 (3H, s, 1-
OMe), 3.55 (3H, s, OMe),  2.77 (1H, dd, J = 15.5, 9.5 Hz, H-2a), 2.54 (1H, m, H-4), 2.44 (1H, 
dd, J = 15.5, 4.5 Hz, H-2b), 2.42 (1H, m, H-5a), 2.41 (2H, t, J = 7.4 Hz, H-8), 2.17 (1H, m, H-
5b), 2.09 (2H, m, H-10), 1.70 (3H, overlapped, H-16), 1.68 (3H, s, H-14), 1.68 (2H, 
overlapped, H-9), 0.89 (3H, d, J = 7.1 Hz, H-7). 
5.3.5. (R)-MTPA ester (28b): Amorphous solid. ESIMS (positive ions): m/z 485 [M + H]+. 1H 
NMR (CDCl3): d 7.32 and 7.55 (MTPA phenyl protons), 6.03 (1H, d, J = 15.9 Hz, H-12), 5.65 
(H-3, m); 5.45 (1H, q, J = 6.9 Hz, H-15), 5.42 (1H, dt, J = 15.9, 6.0 Hz, H-11), 3.72 (3H, s, 1-
OMe), 3.55 (3H, s, OMe),  2.78 (1H, dd, J = 15.5, 9.5 Hz, H-2a), 2.51 (1H, m, H-4), 2.46 (1H, 
dd, J = 15.5, 4.5 Hz, H-2b), 2.40 (1H, m, H-5a), 2.41 (2H, t, J = 7.4 Hz, H-8), 2.15 (1H, m, H-
5b), 2.08 (2H, m, H-10), 1.70 (3H, overlapped, H-16), 1.68 (3H, s, H-14), 1.67 (2H, 
overlapped, H-9), 0.85 (3H, d, J = 7.1 Hz, H-7). 
5.3.6. Manadoperoxide B (24): Colorless amorphous solid; [α]D -5.5 (c 0.2, CHCl3); 
1H NMR 
(CDCl3, 500 MHz) δH 6.03 (1H, d, J = 15.9 Hz, H-12), 5.47 (1H, dt, J = 15.9, 6.0 Hz, H-11), 
5.40 (1H, t, J = 6.1 Hz, H-15), 4.43 (1H, m, H-3), 3.72 (3H, s, 1-OMe), 3.26 (3H, s, 6-OMe), 
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2.97 (1H, dd, J = 15.5, 9.5 Hz, H-2a), 2.57 (1H, m, H-4), 2.44 (1H, dd, J = 15.5, 4.5 Hz, H-2b), 
2.09 (2H, overlapped, H-16), 2.07 (2H, overlapped, H-10), 1.70 (3H, s, H-14), 1.69 (1H, 
overlapped, H-5a), 1.66 (1H, overlapped, H-8a), 1.40 (2H, overlapped, H-9), 1.36 (1H, 
overlapped, H-8b), 1.28 (1H, m, H-5b), 1.00 (3H, t, J = 7.1 Hz, H-17), 0.84 (3H, d, J = 7.1 Hz, 
H-7); 13C NMR (CDCl3, 125 MHz) δC 172.5 (s, C-1), 136.0 (d, C-12), 133.8 (d, C-15), 133.3 (s, 
C-13), 125.8 (d, C-11), 103.4 (s, C-6), 80.2 (d, C-3), 52.2 (q, 1-OMe), 48.8 (q, 6-OMe), 34.6 
(t, C-5), 33.6 (t, C-10), 32.1 (t, C-8), 31.4 (t, C-2), 27.6 (d, C-4), 23.5 (t, C-9), 21.9 (t, C-16), 
17.0 (q, C-7), 15.0 (q, C-17), 13.0 (q, C-14); (+) ESI-MS m/z 341 [M + H]+, 363 [M + Na]+. HR-
ESIMS found 341.2333; C19H33O5 requires 341.2328. 
 
 13C (125 MHz) NMR data of of manadoperoxides A (23), C (25)  
aPos. 23 25 26 
 C (mult.)  C(mult.) C (mult.) 
1       171.9 (C)  172.3 (C)   172.2 (C) 
2         31.8 (CH2)    31.4 (CH2)     31.7 (CH2) 
3  80.1 (CH)    79.8 (CH)     79.7 (CH) 
4  27.6 (CH)    27.1 (CH)     27.2 (CH) 
5  34.6 (CH2)    34.4 (CH2)     34.5(CH2) 
6       103.4 (C)   103.0 (C)   103.0 (C) 
7  17.0 (CH)    17.2 (CH3)     17.1 (CH) 
8  32.4 (CH2)    34.3 (CH2)     31.4 (CH2) 
       9  23.6 (CH2)    21.8 (CH2)     22.0 (CH2) 
10  33.7 (CH2)    32.6 (CH2)     38.4 (CH2) 
11      126.0 (CH)   147.0 (CH)     70.1 (CH) 
12      135.8 (CH)   132.1 (CH)   127.1 (CH) 
13      133.3 (C)   198.7 (C)   142.0 (C) 
14  13.0 (CH3)    27.3 (CH3)     13.7 (CH3) 
15      124.8 (CH)      72.8 (CH) 
16  12.2 (CH3)      17.9 (CH3) 
1-OMe  52.2 (CH3)     52.2 (CH3)     52.2 (CH3) 
6-OMe  48.8 (CH3)     48.8 (CH3)     48.7 (CH3) 
 
5.3.7. Manadoperoxide C (25): Colorless amorphous solid; [α]D -3.3 (c 0.1, CHCl3); 
1H NMR 
(CDCl3, 500 MHz) see Table; 
13C NMR (CDCl3, 125 MHz) see Table; (+) ESI-MS m/z 315 [M + 
H]+, 337 [M + Na]+. HR-ESIMS found 315.1801; C16H27O6 requires 315.1808. 
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5.3.8. Manadoperoxide D (26): Colorless amorphous solid; [α]D -4.2 (c 0.2, CHCl3); 
1H NMR 
(CDCl3, 500 MHz) see Table; 
13C NMR (CDCl3, 125 MHz) see Table; (+) ESI-MS m/z 361 [M + 
H]+, 383 [M + Na]+. HR-ESIMS found 361.2222; C18H33O7 requires 361.2226. 
5.3.9. Reaction of 26 with R- and S-MTPA chlorides: Compound 26 (1.0 mg, 2.8 μmol) was 
treated with R-MTPA chloride (30 μL) in 400 μL of dry pyridine with a catalytic amount of 
DMAP overnight at rt. Then, the solvent was removed and the product was purified by 
HPLC (n-hexane/EtOAc 97:3) to obtain the S-MTPA diester 29a (1.8 mg, 81% yield). When 
compound 26 (1.0 mg, 2.8 μmol) was treated with S-MTPA chloride, following the same 
procedure, 1.7 mg (76% yield) of R-MTPA ester 29b were obtained.   
5.3.10. (S)-MTPA ester (29a): Amorphous solid. ESIMS (positive ions): m/z 793 [M + H]+. 1H 
NMR (CDCl3): d 7.35 and 7.45 (MTPA phenyl protons), 5.61 (1H, m, H-11), 5.45 (1H, d, J = 
8.7 Hz, H-12), 5.41 (1H, q, J = 7.1 Hz, H-15), 4.37 (1H, m, H-3), 3.70 (3H, s, 1-OMe), 3.55 
(6H, s, MTPA-OMe), 3.17 (3H, s, 6-OMe), 2.83 (1H, dd, J = 15.5, 9.5 Hz, H-2a), 2.47 (1H, m, 
H-4), 2.37 (1H, dd, J = 15.5, 4.5 Hz, H-2b), 1.77 (3H, s, H-14), 1.65 (1H, overlapped, H-5a), 
1.60 (1H, m, H-10a), 1.55 (2H, m, H-8), 1.40 (1H, m, H-10b), 1.35 (2H, overlapped, H-9), 
1.35 (1H, overlapped, H-5b), 1.31 (3H, d, J = 7.1 Hz, H-16), 0.78 (3H, d, J = 7.1 Hz, H-7). 
5.3.11. (R)-MTPA ester (29b): Amorphous solid. ESIMS (positive ions): m/z 793 [M + H]+. 1H 
NMR (CDCl3): d 7.32 and 7.55 (MTPA phenyl protons), 5.59 (1H, m, H-11), 5.43 (1H, d, J = 
8.7 Hz, H-12), 5.38 (1H, q, J = 7.1 Hz, H-15), 4.37 (1H, m, H-3), 3.70 (3H, s, 1-OMe), 3.55 
(6H, s, MTPA-OMe), 3.22 (3H, s, 6-OMe), 2.83 (1H, dd, J = 15.5, 9.5 Hz, H-2a), 2.45 (1H, m, 
H-4), 2.37 (1H, dd, J = 15.5, 4.5 Hz, H-2b), 1.75 (3H, s, H-14), 1.65 (1H, overlapped, H-5a), 
1.60 (1H, m, H-10a), 1.55 (2H, m, H-8), 1.37 (1H, m, H-10b), 1.37 (1H, overlapped, H-5b), 
1.34 (2H, overlapped, H-9), 1.29 (3H, d, J = 7.1 Hz, H-16), 0.78 (3H, d, J = 7.1 Hz, H-7). 
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5.4. Synthesis of simplified endoperoxides 
5.4.1. Modified Knoevenagel condensation: A solution of ethyl hydrogen malonate (5.0 g, 
0.040 mol) and piperidinium acetate (36.8 mg, 0.26 mmol) in DMSO (20 mL) was strirred in a 
round-bottom flask for 15 min and then (E)-2-nonenal was (3.4 mL, 0.026 mol) was added at 
once. Stirring was continued for 30 min and then the reaction mixture was heated slightly 
until 85 °C for 4h, following the production of carbon dioxide. After cooling at room 
temperature, the reaction mixture was poured into cold water (40 mL) and extracted with 
diethyl ether (30 mL). The combined extracts were washed with water (3 x 40 mL) and dried 
over anhydrous Na2SO4 and the solvent removed under vacuum. The crude product was 
separated over silica column (eluent n-hexane/EtOAc 9: 1) to give a mixture of Ethyl undeca-
3Z,5E-dienoate (3), Ethyl undeca-3E,5E-dienoate (4), Ethyl undeca-2E,4E-dienoate (2). All the 
attempts to further purify this crude mixture over silica columns failed and also HPLC 
purifications gave no pure products. A portion of the obtained mixture was separated into its 
constituents through Ag+-impregnated silica gel column, eluting with n-hexane/EtOAc 
mixtures from 95:5 to 8:2 and obtaining ethyl undeca-3Z,5E-dienoate (3), ethyl undeca-
3E,5E-dienoate (4), and ethyl undeca-2E,4E-dienoate (2). 
5.4.2. Ethyl undeca-3E,5Z-dienoate (3): Colorless oil. EIMS: m/z 210 [M]+, HREIMS: m/z 
210.1613, calcd. for C13H22O2 m/z 210.1620. 
1H NMR (CDCl3): d 6.42 (H-4, dd); 5.98 (H-5, dd); 
5.73 (H-6, dt); 5.42 (H-3, dt); 4.10 (OCH2, q); 3.13 (H-2, d); 2.16 (H-7, m); 1.30-1.20 (H2-8, H2-9, 
H2-10, m); 1.15 (OCH2CH3, t);  0.88 (H3-11, t, J = 7.3 Hz). 
5.4.3. Ethyl undeca-3E,5E-dienoate (4): Colorless oil. EIMS: m/z 210 [M]+, HREIMS: m/z 
210.1627, calcd. for C13H22O2 m/z 210.1620. 
1H NMR (CDCl3): d 6.08 (H-4, dd, J =15.1, 10.3 
Hz); 5.99 (H-5, dd, 15.1, 10.3 Hz); 5.64 (H-6, m); 5.56 (H-3, dt, J = 15.1, 7.0 Hz); 4.10 (OCH2, q, 
J = 7.2 Hz); 3.06 (H-2, d, J = 7.0 Hz); 2.05 (H-7, m); 1.30-1.20 (H2-8, H2-9, H2-10, m); 1.15 
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(OCH2CH3, t, J = 7.2 Hz);  0.88 (H3-11, t, J = 7.0 Hz).
 13C NMR (CDCl3): d 172.0 (C-1); 135.3 (C-6); 
134.2 (C-4); 129.5 (C-5); 122.5 (C-3); 61.0 (OCH2CH3); 38.0 (C-2); 29.7-29.5 (C-8; C-9; C-10); 
25.7 (C-7); 14.6 (OCH2CH3); 14.1 (C-11). 
5.4.4. Ethyl undeca-2E,4E-dienoate (2): Colorless oil. EIMS: m/z 210 [M]+, HREIMS: m/z 
210.1615, calcd. for C13H22O2 m/z 210.1620. 
1H NMR (CDCl3): d 7.30 (H-3, dd); 5.94 (H-2, d); 
5.86 (H-4, dd); 5.68 (H-5, dt); 4.10 (OCH2, q); 2.20 (H-6, m); 1.30-1.20 (H2-7, H2-8, H2-9, H2-10, 
m); 1.15 (OCH2CH3, t);  0.90 (H3-11, t, J = 7.3 Hz). 
5.4.5. Photo-oxygenation reaction: A solution of compound 4 in CHCl3/MeOH 95:5 (120 mL) 
was photolysed with a 500 W halogen lamp in the presence of methylene blue  (0.6 mg) as 
photosensitizer, through which was bubbled a constant stream of oxygen at a flow rate of 50 
mL/min for 24 hrs. The reaction was performed in a Pyrex flask fitted with an external cooling 
jacket. The reaction mixture was then concentrated in vacuo and the resulting residue was 
purified by column choromatography (n-hexane/EtOAc mixtures from 99:1 to 9:1) to yield 
pure compound 5 in almost quantitative yields. When the same reaction was repeated in the 
same conditions for the mixture of dienes 2-4, after chromatographic purification the single 
endoperoxide 5 was obtained.  
5.4.6. Compound 5: Colorless oil. EIMS: m/z 242 [M]+, HREIMS: m/z 242.1515, calcd. for 
C13H22O4 m/z 242.1518. 
1H NMR (CDCl3): d 5.93 (H-4, overlapped); 5.91 (H-5, overlapped); 
4.83 (H-3, m); 4.60 (H-6, m); 4.08 (OCH2, q, J = 7.2 Hz); 2.85 (H-2a, dd); 2.60 (H-2b, dd); 1.56 
(H2-7, m); 1.25-1.20 (H2-8, H2-9, H2-10, m); 1.15 (OCH2CH3, overlapped); 0.88 (H3-11, t, J = 7.0 
Hz). 13C NMR (CDCl3): d 170.8 (C-1); 129.5 (C-5); 126.7 (C-4); 78.6 (C-6); 75.2 (C-3); 61.0 
(OCH2CH3); 38.8 (C-2); 32.7 (C-7); 32.0 (C-10); 22.8 (C-8; C-9); 14.6 (OCH2CH3); 14.4 (C-11). 
5.4.7. LiBH4-mediated reduction of compound 5 and acetylation of the product: Compound 
5  (12.0 mg, 0.050 mmol) was dissolved in 0.8 mL of dry THF under argon flow at 0 °C and 
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then 150 μL of a 2 M solution of LiBH4 in THF (0.3 mmol) and 10 μL of dry MeOH were added 
dropwise to the solution. The reaction was kept under stirring for 2 h at 0 °C. Then, 10 μL of 1 
M aqueous NaOH were added to the obtained mixture, which was partitioned between 
water and CHCl3. The organic phase, dried with Na2SO4 and concentrated in vacuo was 
purified by HPLC (eluent n-hexane/EtOAc 75:25) affording pure compound 6 (9.0 mg, 0.045 
mmol, 90 % yield). Compound 6 (3.0 mg, 0.015 mmol) was dissolved in dry pyridine (1 mL) 
and treated with Ac2O (1 mL). After standing overnight, the reaction was worked up by 
addition of a few drops methanol to destroy the excess Ac2O, water (ca. 3 mL) and EtOAc (ca. 
10 mL). The organic phase was washed sequentially with 2N H2SO4, saturated NaHCO3 and 
brine. After drying (Na2SO4) and removal of the solvent, 3.0 mg (0.012 mmol) of compound 7 
were obtained. 
5.4.8. Compound 6: Colorless solid. EIMS: m/z 200 [M]+, HREIMS: m/z 200.1422, calcd. for 
C11H20O3 m/z 200.1412. 
1H NMR (CDCl3): d 5.90 (H-4, overlapped); 5.90 (H-5, overlapped); 
4.63 (H-3, m); 4.55 (H-6, m); 3.80 (H2-1, m); 1.88 (H2-2, m); 1.62 (H2-7, m); 1.31 (H2-8, H2-9, 
H2-10, m); 0.88 (H3-11, t, J = 7.0 Hz). 
5.4.9. Compound 7: Colorless solid. EIMS: m/z 200 [M]+, HREIMS: m/z 200.1527, calcd. for 
C13H22O4 m/z 200.1518. 
1H NMR (CDCl3): d 5.91 (H-4, overlapped); 5.91 (H-5, overlapped); 
4.58 (H-3, overlapped); 4.58 (H-6, overlapped); 4.22 (H2-1, m); 2.08 (CH3CO, s); 1.92 (H2-2, m); 
1.62 (H2-7, m); 1.31 (H2-8, H2-9, H2-10, m); 0.88 (H3-11, t, J = 7.0 Hz). 
5.4.10. Hydrolysis of compound 5: Compound 5 (9.0 mg, 0.037 mmol) was dissolved in a 
THF/H2O 3:1 solution (3.0 mL) and 4 mg of LiOH were added. The solution was stirred at 0 °C 
overnight. Then, the reaction mixture was partitioned between EtOAc and water. The organic 
phase, evaporated to dryness, contained compound pure compound 8 (7.0 mg, 0.033 mmol). 
5.4.11. Compound 8: Colorless oil. EIMS: m/z 214 [M]+, HREIMS: m/z 214.1215, calcd. for 
Chapter 5                                                                                                          Experimental Section 
 
 89 
C13H22O4 m/z 214.1205. 
1H NMR (CD3OD): d 5.90 (H-4, d); 5.68 (H-5, d); 5.15 (H-3, m); 4.95 (H-
6, m); 2.75 (H-2a, dd); 2.55 (H-2b, dd); 1.56 (H2-7, m); 1.25-1.20 (H2-8, H2-9, H2-10, m); 0.88 
(H3-11, t, J = 7.0 Hz).
  
5.4.12. Dihydroxylation of compound 5: To a stirred solution of compound 5 (10 mg, 0.042 
mmol) in t-BuOH (2.5 mL) and water (2.5 mL) was added K2OsO4 (0.5 mol %) and citric acid, 
followed by NMO (5.1 mg). The mixture was stirred for 3 hours and followed by TLC. Then, 
the reaction mixture was extracted with CH2Cl2, dried over Na2SO4 concentrated in vacuo and 
the product purified by HPLC (normal phase n-hexane/EtOAc 1:1) to obtain compound 10 
(8.1 mg, 0.029 mmol).   
5.4.13. Compound 10: Colorless solid. EIMS: m/z 276 [M]+, HREIMS: m/z 276.1579, calcd. for 
C13H24O6 m/z 276.1573. 
1H NMR (CDCl3): d 4.59 (H-3, m); 3.79 (H-6, m); 3.68 (H-4, 
overlapped); 3.61 (H-5, m); 4.08 (OCH2, q, J = 7.2 Hz); 2.78 (H-2a, dd); 2.60 (H-2b, dd); 1.60 
(H2-7, m); 1.25-1.20 (H2-8, H2-9, H2-10, m); 1.15 (OCH2CH3, overlapped); 0.88 (H3-11, t, J = 7.0 
Hz). 
5.4.14. Epoxidation of compound 5. Compound 5 (18.0 mg, 0.074 mmol) was dissolved in 2.5 
mL of dry CH2Cl2 and 130 mg of meta-chloroperbenzoic acid (0. 74 mmol) were added to the 
solution that was then stirred overnight at room temperature. Subsequently, the reaction 
mixture was partitioned between CHCl3 and saturated aqueous NaHCO3. The organic phase, 
dried and concentrated in vacuo, was then purified by reversed-phase HPLC (eluent 
MeOH/H2O 9:1) yielding compounds 11 (9.6 mg) and 12 (2.5 mg) in the pure state. 
5.4.15. Compound 11 Colorless solid. EIMS: m/z 258 [M]+, HREIMS: m/z 258.1477, calcd. for 
C13H22O5 m/z 258.1467. 
1H NMR (CD3OD): d 4.76 (H-3, m); 4.30 (H-6, m); 3.60 (H-4, m); 3.32 
(H-5, m); 4.18 (OCH2, q, J = 7.2 Hz); 2.90 (H2-2, m); 1.60 (H2-7, m); 1.45 (H2-8, m); 1.33-1.30 
(H2-9, H2-10, m); 1.30 (OCH2CH3, overlapped); 0.90 (H3-11, t, J = 7.0 Hz).
 13C NMR (CDCl3): d 
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170.8 (C-1);  83.7 (C-6); 74.1 (C-3); 60.7 (OCH2CH3); 51.5 (C-4); 48.9 (C-5); 37.5 (C-2); 32.0 (C-
7); 32.8 (C-8; C-9); 23.5 (C-10); 14.1 (C-11); 13.4 (OCH2CH3). 
5.4.16. Compound 12 Colorless solid. EIMS: m/z 258 [M]+, HREIMS: m/z 258.1473, calcd. for 
C13H22O5 m/z 258.1467. 
1H NMR (CD3OD): d 4.70 (H-3, m); 4.37 (H-6, m); 3.37 (H-4, m); 3.25 
(H-5, m); 4.13 (OCH2, q, J = 7.2 Hz); 2.92 (H-2a, dd); 2.78 (H-2b, dd); 1.62 (H2-7, m); 1.45 (H2-8, 
m); 1.33-1.30 (H2-9, H2-10, m); 1.29 (OCH2CH3, overlapped); 0.90 (H3-11, t, J = 7.0 Hz).
 13C 
NMR (CDCl3): d 170.4 (C-1);  78.8 (C-6); 74.7 (C-3); 61.2 (OCH2CH3); 51.3 (C-4); 47.9 (C-5); 36.0 
(C-2); 32.0 (C-7); 32.1 (C-8; C-9); 23.0 (C-10); 14.1 (C-11); 13.4 (OCH2CH3). 
5.4.17. Bromination of compound 5: Bromine (12.5 mg, 0.078 mmol) was added in the dark 
to a solution of compound 5 (15 mg, 0.062 mmol) in CH2Cl2 (2.0 mL) in a vial kept at 0 °C. 
After 15 minutes the solvent was removed under a stream of nitrogen and the residue was 
purified by HPLC (normal phase n-hexane/EtOAc 85:15) to yield compounds 13 (16.3 mg, 
0.041 mmol) and 14 (7.1 mg, 0.018 mmol).  
5.4.18. Compound 13: Colorless solid. EIMS: m/z 400 [M]+, HREIMS: m/z 399.9888, calcd. for 
C13H22
79Br2O4 m/z 399.9885. 
1H NMR (CDCl3): d 5.17 (H-3, m); 4.80 (H-4, m); 4.32 (H-5, m); 
4.18 (H-6, m); 4.10 (OCH2, q, J = 7.2 Hz); 2.82 (H-2a, dd); 2.72 (H-2b, dd); 1.45 (H2-7, m); 1.33-
1.30 (H2-8, H2-9, H2-10, m); 1.20 (OCH2CH3, overlapped); 0.92 (H3-11, t, J = 7.0 Hz). 
5.4.19. Compound 14: Colorless solid. EIMS: m/z 400 [M]+, HREIMS: m/z 399.9882, calcd. for 
C13H22
79Br2O4 m/z 399.9885. 
1H NMR (CDCl3): d 4.84 (H-3, m); 4.25 (H-6, m); 4.20 (H-4, m); 
3.80 (H-5, m); 4.10 (OCH2, q, J = 7.2 Hz); 2.92 (H-2a, dd); 2.88 (H-2b, dd); 1.48 (H2-7, m); 1.33-
1.30 (H2-8, H2-9, H2-10, m); 1.20 (OCH2CH3, overlapped); 0.90 (H3-11, t, J = 7.0 Hz). 
5.5. Theonella swinhoei 
5.5.1. Animal material, extraction, isolation: A specimen of Theonella swinhoei (order 
Lithistida, family Theonellidae) was collected in January 2008 along the coasts of the 
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Bunaken island in the Bunaken Marine Park Park (North Sulawesi, Indonesia). The species 
is very common in this area, from 20 to 50 m depth, on substrata subjected to strong 
currents. In vivo, the sponge is red-orange but specimens living in shadow habitats are 
pale pink to white. It is frequently exploited as food by fishes and turtles. A voucher 
sample has been deposited at the Dipartimento di Chimica delle Sostanze Naturali, 
Università di Napoli Federico II. After homogenization, the organism (wet weight 560.2 g) 
was exhaustively extracted, in sequence, with methanol and dichloromethane. The 
combined extracts were partitioned between water and EtOAc and the obtained organic 
extract (2.6 g) was subjected to chromatography over silica column (230-400 mesh) eluting 
with a solvent gradient of increasing polarity of n-hexane/EtOAc/MeOH. Fractions eluted 
with EtOAc/MeOH 9:1 were combined and further purified by reverse-phase HPLC (eluent 
MeOH/H2O 65:35) to obtain aurantoside G (47, 12.4 mg). Fractions eluted with n-
hexane/EtOAc 3:7 were combined and further purified by reverse-phase HPLC (eluent 
MeOH/H2O 85:15) to obtain aurantoic acid (45, 2.5 mg). Fractions eluted with n-
hexane/EtOAc 7:3 were combined and subjected to normal phase HPLC (n-hexane/EtOAc 
75:25) to obtain conicasterol (48, 75.2 mg) and theonellasterol (49, 63.4 mg). The crude 
sterol fraction was also peracetylated with an excess of Ac2O in dry pyridine and subjected 
to GC/MS analysis with the following gradient: initial 200°C (3.5 min), increment of 
10°C/min to reach 330 °C, inlet 270 °C, transfer line 280°C, ion source 250 °C, blink window 
3.5 min. Theonellasterol acetate (min. 13.18, m/z 468), conicasterol acetate (min. 12.49, 
m/z 454) and dehydroconicasterol acetate (min. 12.42, m/z 452) were detected. The crude 
sterol fraction was also chromatographed through a Ag+-impregnated silica gel column, 
eluting with n-hexane/EtOAc mixtures from 95:5 to 55:45. Fractions eluted with n-
hexane/EtOAc 65:35 afforded dehydroconicasterol (46, 4.8 mg) in the pure state.  
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5.5.2. Aurantoic Acid (45): Yellow amorphous solid; UV-vis (MeOH) λmax 346 (ε 20100), 363 
(ε 18500), 1H NMR (CDCl3, 500 MHz) δH 7.31 (1H, dd, J = 15.4, 11.5 Hz, H-3), 6.69 (1H, dd, J 
= 14.9, 11.2 Hz, H-5), 6.60 (1H, dd, J = 15.3, 10.6 Hz, H-9), 6.54 (1H, dd, J = 15.0, 11.3 Hz, H-
7), 6.43 (1H, dd, J = 14.9, 11.0 Hz, H-4), 6.41 (1H, dd, J = 15.3, 11.3 Hz, H-8), 6.39 (1H, dd, J 
= 15.0, 11.2 Hz, H-6), 6.26 (1H, d, J = 10.6 Hz, H-10), 5.86 (1H, d, J = 15.4 Hz, H-2), 2.19 (3H, 
bs, H-12); 13C NMR (CDCl3, 125 MHz) δC 169.1 (s, C-1), 145.0 (d, C-3), 140.7 (d, C-5), 139.0 
(d, C-6), 137.0 (d, C-7), 132.7 (d, C-8), 132.6 (s, C-11), 130.1 (d, C-4), 130.0 (d, C-9), 125.4 
(d, C-10), 120.6 (d, C-2), 25.3 (q, C-12). (+) ESI-MS m/z 225 and 227 (3:1) [M + H]+, m/z 247 
and 249 (3:1) [M + Na]+. HR-ESIMS found m/z 247.0505; C12H13
35ClO2Na req. m/z 
247.0502.  
13C (125 MHz) and 1H (500 MHz) NMR Data for Dehydroconicasterol (46) in CDCl3 
Posit.  H (mult., J in Hz) C (mult.) Posit. H (mult., J in Hz) C (mult.) 
1a 1.76a  36.7 (CH2) 16a        1.58
a 24.6 (CH2) 
1b 1.32a  16b 1.37a  
 
2a 
2.01 (ddt, 12.8, 7.3, 4.0)  33.1 (CH2) 17 1.16
a 57.0 (CH) 
2b 1.37a 31.8 (CH2) 18 0.83 (s) 18.2 (CH3) 
3 4.04 (dd, 11.0, 4.0) 73.4 (CH) 19 0.58 (s) 13.7 (CH3) 
4  153.1 (C) 20 1.50a 34.3 (CH) 
5 1.82a   49.4 (CH) 21 0.96, (d, 7.3) 19.1 (CH3) 
6a 1.85a 27.0 (CH2) 22a 1.59
a 34.4 (CH2) 
6b 1.40a  22b 1.24a  
7 2.25 (m) 25.8 (CH2) 23a 2.09
a  25.8 (CH2) 
8  125.7 (C) 23b 1.90 (dt, 12.4, 3.0)  30.9 (CH2) 
9 1.79a  49.1 (CH) 24   156.8 (C) 
10   40.1 (C) 25 2.22 (hep, 7.3)  33.9 (CH) 
11a 1.64a   20.4 (CH2) 26 1.03 (d, 7.3)  22.0 (CH3) 
11b 1.57a   27 1.01 (d, 7.3)  22.0 (CH3) 
12a 1.94a 37.5 (CH2) 28a 4.71 (bs)  105.8 (CH2) 
12b 1.13a      28b 4.65 (bs)      
13  42.8 (C) 29a 5.07 (bs)  102.8 (CH2) 
14  142.9 (C) 29b 4.63 (bs)  
15a 2.47 (ddd, 14.5, 4.0, 2.0) 29.4 (CH2)    
15b 1.74a     
a Overlapped with other signals 
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5.5.3. Dehydroconicasterol (46): Colorless amorphous solid; [α]D + 82.1 (c 0.2, CHCl3); ; 
UV-vis (MeOH) λmax 237 (ε 1450),   
1H NMR (CDCl3, 500 MHz) see Table; 
13C NMR (CDCl3, 
125 MHz) see Table; (+) EI-MS m/z 410 [M]+. HR-EIMS found m/z 341.2333; C29H46O 
requires m/z 410.3549. 
5.6. Plakortis simplex  
5.6.1. Animal material, Extraction and Isolation Procedure. 
A specimen of Plakortis simplex was collected in July 2002 along the coasts of The 
Bahamas. A voucher specimen is deposited at the Dipartimento di Chimica delle Sostanze 
Naturali, Italy with the ref. n° 02-10. The organism was immediately frozen after collection 
and kept frozen until extraction, when the sponge (43 g, dry weight after extraction) was 
homogenized and extracted with methanol (4 × 500 mL) and with chloroform (4 × 500 mL). 
The methanol extract was initially partitioned between H2O and n-BuOH and then the 
organic phase was combined with the CHCl3 extract and concentrated in vacuo to afford a 
brown oil (22.1 g). This was subjected to chromatography on a column packed with RP18 
silica gel and eluted with 9:1 H2O/MeOH (A1), 7:3 H2O/MeOH (A2), 4:6 H2O/MeOH (A3), 2:8 
H2O/MeOH (A4), MeOH (A5), and 9:1 MeOH/CHCl3 (A6). Fraction A3 (442 mg) was further 
chromatographed by MPLC (SiO2 230-400 mesh; solvent gradient system of increasing 
polarity from EtOAc to MeOH). Fractions eluted with EtOAc/MeOH 2:8 were re-
chromatographed by reverse-phase HPLC (eluent MeOH/H2O 4:6) affording pure 
simplexidine (52, 2.0 mg).  
5.6.3. Simplexidine (52) Colorless amorphous solid. [α]D 25 –5.8 (c = 2.0 mg/mL in MeOH); 
IR (KBr): λmax 1642, 1078, 922 cm-1; UV (MeOH): λmax 268 (logε -3.41); ESI-MS (negative 
ions): m/z 246 (M-H)-. ESI-MS (positive ions): m/z 248 (M+H)+, 270 (M+Na)+. HR-FABMS 
analysis: m/z 248.1647 (M+H)+, calcd. For C15H22NO2 m/z 248.1651. 1H- and 13C-NMR:  
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1H (500 MHz) and 13C (125 MHz) NMR Data of Simplexidine (52) in CD3OD  
 
 
5.7 Evaluation of antimalarial activity 
Plasmodium falciparum cultures were carried out according to Trager and Jensen’s89 with 
slight modifications. The CQ-sensitive, moderately mefloquine-resistant clone D10, the 
CQ-resistant, mefloquine-susceptible clone W2 were maintained at 5% haematocrit 
(human type A-positive red blood cells) in complete culture medium at 37 °C. Complete 
medium contained RPMI 1640 medium (Gibco BRL, NaHCO3 24 mM) with the addition of 
10% heat-inactivated A-positive human plasma, 20mM Hepes (Biological Industries, 
Kibbutz, Israel), 2mM Glutammine (Biological Industries, Kibbutz, Israel). All the cultures 
were maintained in a standard gas mixture consisting of 1% O2, 5% CO2, 94% N2. When 
parasitemia exceeded 5%, subcultures were taken; the culture medium was changed 
every second day. 
Compounds were dissolved in either water (chloroquine) or DMSO and then diluted with 
medium to achieve the required concentrations (in all cases the final concentration 
contained <1% DMSO, which was found to be non-toxic to the parasite). Drugs were 
Pos. H, mult., J in Hz  C, mult. Pos. H, mult., J in Hz  C, mult. 
1 0.93, t, 7.3 14.5,CH3    
2 1.97, q, 7.3 25.8, CH2 2’ 8.81, s 143.1, CH 
3 5.48, dt, 15.4, 7.3 136.2, CH 3’  141.9, C 
4 5.35, dt, 15.4, 7.0 126.2, CH 4’  163.5, C 
5 2.43, q, 7.0 38.1, CH2 5’ 7.91, d, 6.9 127.3, CH 
6 3.81, m 43.4, CH 6’ 8.63, d, 6.9 143.4, CH 
7a 1.87, m  27.7, CH2 7’  168.6, C 
7b 1.73, m  8’ 4.34, s 46.7, CH3 
8 0.89, t, 7.5 12.2, CH3    
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placed in 96 wells flat-bottom microplates (Costar # 3596) and serial dilution made. 
Asynchronous cultures with parasitemia of 1-1.5% and 1% final haematocrit were 
aliquoted into the plates and incubated for 72 hours at 37 °C. Parasite growth was 
determined spectrophotometrically (OD650) by measuring the activity of the parasite 
lactate dehydrogenase (LDH), according to a modified version of the method of Makler90,91 
in control and drug-treated cultures. Antimalarial activity was expressed as the 50% 
inhibitory concentrations (IC50, μM); each IC50 value presented in the Tables is the mean 
and standard deviation of four separate experiments performed in triplicate.
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1H NMR spectrum (500 MHz) of compound 9a in CDCl3 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1H NMR spectrum (500 MHz) of compound 8a in CDCl3 
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COSY spectrum  (500MHz) of manadoperoxide A (23) in CDCl3 
  
         
HMBC spectrum (500MHz) of manadoperoxide A (23) in CDCl3 
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1H NMR spectrum (500 MHz) of manadoperoxide B (24) in CDCl3 
 
          
 
 
COSY spectrum (500MHz) of manadoperoxide B (24) in CDCl3 
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1H NMR spectrum (500 MHz) of manadoperoxide C (25) in CDCl3 
 
            
 
HMBC spectrum (500MHz) of manadoperoxide C (25) in CDCl3 
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1H NMR spectrum (500 MHz) of compound 35 in CDCl3 
         
COSY spectrum (500 MHz) of compound (35) in CDCl3 
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HMBC spectrum (500MHz) of compound 35 in CDCl3 
  
 
 
 
COSY spectrum (500MHz) of compound 42 in CDCl3 
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HMBC spectrum (500MHz) of compound 42 in CDCl3 
 
 
1H NMR spectrum (500 MHz) of compound 44 in CDCl3 
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COSY spectrum (500MHz) of compound 44 in CDCl3 
 
   
 
 
HMBC spectrum (500MHz) of compound 44 in CDCl3 
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1H NMR spectrum (500 MHz) (vinylic protons region) of aurantoic acid (45) in CDCl3 
 
 
 
 
 
 
 
 
13C NMR spectrum (500 MHz) of aurantoic acid (45) in CDCl3 
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1H NMR spectrum (700 MHz) of dehydroconicasterol (46) in CDCl3 
 
13C NMR spectrum (500 MHz) of dehydroconicasterol (46) in CDCl3 
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COSY spectrum (700 MHz) of dehydroconicasterol (46) in CDCl3 
 
 
 
 
 
 
                
 
 
 
HMBC spectrum (700 MHz) of dehydroconicasterol (46) in CDCl3
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